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 Hepatitis C virus (HCV) infects nearly 170 million individuals worldwide and remains one 
of the leading causes of cirrhosis and hepatocellular carcinoma. Approximately 15-20% of 
individuals will spontaneously clear the infection, with the CD8+ T cell response crucial in 
achieving control. Given the highly diverse nature of HCV, the T cell response elicited by 
vaccines against HCV must achieve maximum cross reactivity against widely divergent circulating 
strains. We assessed T cell recognition of potential hepatitis C virus vaccine sequences 
generated using three rational approaches: 1) combining epitopes with predicted tight binding to 
the major histocompatibility complex (MHC), 2) consensus sequence (most common amino acid 
at each position), and 3) representative ancestral sequence that had been derived using 
Bayesian phylogenetic tools. No correlation was seen between peptide MHC binding affinity and 
frequency of recognition as measured by an interferon-gamma T cell response in human 
leukocyte antigen-matched HCV infected individuals. CD8+ T cells expanded with representative 
sequence HCV generally more broadly and robustly recognized highly diverse circulating HCV 
strains than T cell expanded with either consensus sequence or naturally occurring sequence 
variants. These data support the use of representative sequence in HCV vaccine design. In 
addition, we hypothesized that ongoing recognition of antigen with continued T cell receptor 
signaling is associated with upregulation of inhibitory T cell receptors. We characterized evolution 
of the CD8+ T cell response in the setting of absent, partial or incomplete, and complete 
recognition of antigen over time to determine if there is an association between prolonged 
antigenic stimulation and expression of inhibitory receptors. HCV-specific CD8+ T cell from HCV-
infected subjects in a prospective longitudinal cohort were phenotyped for the activation markers 
HLA-DR and CD38; co-inhibitory receptors PD-1, TIM-3 and 2B4; and the memory molecule 
CD127 using polychromatic flow cytometry. The phenotype of these cells was compared in the 
setting of intact, mutated, and absent viral antigen within and across subjects. Our data point to 
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This body of work seeks to examine the interplay between hepatitis C virus infection in 
humans and the resultant CD8+ T cell response. Whereas the majority of humans will progress to 
chronic infection, a minority will spontaneously clear the infection. The rapid rate of replication 
and half–life of the virus guarantees that the immune response must defend against an evolving 
and diverse virus. In general, generating a successful adaptive immune response against a virus, 
whether through spontaneous clearance of the virus or through vaccination, requires shared 
responses across hosts. In thinking about this problem in the setting of HCV, I was confronted not 
only with a genetically diverse virus, but also a cohort of genetically similar-- but not identical-- 
hosts. I therefore became interested in combining informatics approaches and more classical 
immunology techniques to study the immune response. 
Based on the earlier work in the lab, I had noted that the CD8+ T cell response was 
heterogeneous across T cell epitopes or within an epitope across time. This insight has led to the 
applications of technologies to quantify how this T cell heterogeneity impacts sequence selection 
for a candidate vaccine sequence as well as phenotyping this heterogeneity on a cellular basis. 
This chapter will orient the reader to the fundamental principles of hepatitis C viral infection, 
genetic diversity, and the previously described mechanisms by which it is known to evade the 
immune system. The conclusion will then provide an overview of the hypotheses, aims, and 
experiments of this research. 
 
Hepatitis C cellular epidemiology 
HCV infection is found in virtually every region of the world, and an estimated 170 million 
persons are infected with HCV worldwide (1). In the United States, there are approximately four 
million persons with persistent hepatitis C infection and more than 10 thousand HCV-related 
deaths each year, with mortality from HCV expected to double in this decade and possibly 
surpass that caused by HIV (2-4). Morbidity and mortality occur in the setting of chronic infection. 
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Chronic HCV may cause cirrhosis and is the most common indication for liver transplantation in 
the United States. In addition, HCV is the major cause of hepatocellular carcinoma in the United 
States, Europe, Japan, Australia, and many other parts of the world (4-8). Although HCV induces 
both antibody (Ab) and T cell responses, the virus evades them effectively in most cases, with 
75% of those exposed becoming chronically infected. 
 
HCV sequence variability 
A major challenge in the study of HCV immunology in humans is the high variability of the 
antigen, which varies not only from person to person, but also at any instant and over time within 
an infected individual. HCV exists in each infected host as a swarm of genetically-related but 
distinct variants, collectively called a quasispecies (9-13). This characteristically diverse set of 
viruses in an individual is not completely random, but rather appears to be driven by the host 
immune system and balanced by functional constraints (14-17). As a result, each collection of 
HCV genomes in a quasispecies has a distinctive set of shared characteristics that allow it to be 
distinguished from others (18). The random generation of sequences results in mutations that 
may be deleterious or neutral, or offer a selective advantage to the virus because they increase 
replication efficiency or permit evasion of the immune response. 
 
Hepatitis C cellular immunology 
Most viral infections induce successful immune responses and do not persist. HCV has 
developed mechanisms to evade immune elimination, thereby allowing it to persist in the liver in 
the majority of infected individuals. The immune correlates that determine whether a patient 
resolves infection or proceeds to chronic infection are not well defined. Previous studies have 
shown that spontaneous clearance of HCV infection occurs in association with a broadly specific 
and vigorous cellular immune response (19-22). In contrast, chronic infection is characterized by 
low frequencies of specific CD8 T cells in peripheral blood (23-28). Experiments performed with in 
vitro model systems have demonstrated mechanisms by which HCV subverts the innate antiviral 
responses needed to stimulate lymphocyte effector functions (29-31). This may partially explain 
 3 
impaired generation of an effective immune response to HCV, but it is unclear how subversion of 
the innate immune response differs between hosts or how those differences would affect 
downstream adaptive immune responses.  
CD4 T cell responses in humans are more frequently detected and more durable in those 
who control HCV infection than in those with chronic HCV infection and CD4 T cell responses 
seen in those who progress to chronic infection have been associated with transient control of 
HCV RNA (21,22,32,33) . Chimpanzee data support the importance of CD4 T cell responses in 
control of infection (34). CD8 T cells are also critical to control of HCV and the appearance of 
HCV-specific CD8 T cells in liver and blood is kinetically associated with control of viremia 
(35,36). While virus specific CD4 and CD8 T cell responses play a role, generation of a cellular 
immune response does not ensure control of infection. A detectable cellular immune response is 
usually present in early infection regardless of outcome and that response may even persist into 
chronic infection (37). It is unclear why those immune responses fail to control infection, but we 
and others have demonstrated that the responses generated in acute infection decline in subjects 
who remained persistently infected (21,36-38). Most subjects with detectable cellular immune 
responses during the acute phase of infection had gradual loss of responses, in both breadth and 
magnitude, during the chronic phase of infection. Despite ongoing viremia and ample evidence 
that HCV sequence varies during acute and chronic infection, those persistently infected did not 
develop new epitope specificities after the first six months of infection. Taken together, these 
results suggest that development of HCV-specific T cells is arrested during the first year of 
chronic infection.  
 
Hepatitis C escape from the immune response 
The decline in T cell responses to HCV is poorly understood, but escape is a likely 
contributing factor. Because immune responses develop over weeks and pathogens replicate on 
the order of hours or days, it is well-recognized that immune escape mutations may blunt the 
effectiveness of the immune response (39). Mathematical models of viral kinetics suggest that up 
to 10
12
 virions are produced each day in a chronically HCV infected human (40). The high level of 
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virion turnover, coupled with the absence of proofreading by the HCV RNA polymerase, results in 
frequent mutations within the viral genome. Mutation of class I or II major histocompatibility 
complex (MHC) restricted T cell epitopes may alter the outcome of infection by preventing or 
delaying clearance of infected hepatocytes (41). In the face of a vigorous multi-specific cytotoxic 
lymphocyte (CTL) response, mutation of several epitopes, perhaps simultaneously, would be 
required for survival of the virus. In the chimpanzee model, antibody-mediated CD4 T cell 
depletion prior to HCV infection does not prevent initial CD8 T cell responses in a previously-
exposed animal, but does impair viral control in association with epitope escape mutations in the 
viral sequence (34). Longitudinal analysis during chronic infection demonstrated a very low rate of 
amino acid substitution in CTL epitopes, suggesting that CTL escape that occurs may be limited 
to early infection (42). 
 
Selection of mutations within T cell epitopes with HCV sequence variation and T cell evasion 
To test the hypothesis that immune escape occurs during progression to chronic 
infection, we compared sites of T cell epitopes with viral amino acid replacements (17). For 
subjects with persistent viremia and T cell responses, amino acid substitutions were a median of 
16.7 fold more likely to occur within T cell epitopes than outside epitopes (range 11.4-24.9). In 
general, substitutions in recognized epitopes tested resulted in decreased recognition by T 
lymphocytes compared to recognition of the sequence present at initial viremia, indicating 
escape. Therefore, virus-specific T cells select for mutants that are not recognized as well by 
those T cells.  
 
Mechanisms through which mutations permit T cell evasion. 
Reduced recognition may result from changes in the epitope sequence itself or in flanking 
residues that are involved in antigen processing (43). Evasion of the immune response via 
substitution within T cell epitopes occurs during HCV, HBV, SIV, and HIV infections via two 
known mechanisms: decreased MHC binding and impaired antigen processing or presentation 
(17,43-51). Substitutions within T cell epitopes that do not decrease MHC binding or impair 
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antigen processing or presentation have been observed in multiple chronic viral infections, and 
substitutions affecting T cell receptor (TCR) engagement have been proposed to explain 
selection of these mutations. While impaired TCR engagement may allow immune escape, a new 
T cell repertoire should be available to recognize such neoepitopes. We recently identified a 
novel mechanism for impaired T cell recognition of a mutation involving a TCR contact residue in 
HCV (52). 
 
A novel mechanism for impaired T cell recognition of a mutation involving a TCR contact residue 
Substitutions in TCR contact residues would be expected to lead to only transient 
immune escape in immunocompetent hosts since the new epitope should be recognized by a 
distinct repertoire of T cells specific for the substituted epitope. In addition to identifying multiple 
mutations which decrease or abrogate HCV peptide binding to the human leukocyte antigen 
(HLA), we identified an amino acid substitution that reduces T cell recognition due to impaired 
engagement of the TCR with the variant peptide/A*0201 complex. The mutated peptide was not 
an antagonist, nor did it affect HLA binding affinity nor prevent antigen processing and 
presentation. However, it failed to expand T cells primed against the original sequence, poorly 
activated T cells specific for the original antigen to secrete cytokines, and weakly engaged the 
TCR when complexed to MHC (52). We determined that the failure to mount a better response to 
the peptide observed later in infection represented poor intrinsic immunogenicity of this variant 
because of a ‘hole in the repertoire’. This is reflected by an absence or paucity within the primary 
repertoire of T cells containing high affinity TCR with specificity for that variant. There was a 
dramatic difference between the ability of the original and variant peptides to prime responses 
from the primary naïve T cell repertoires in HLA A*0201
+
 individuals never exposed to HCV. The 
variant virus is highly inefficient at priming naïve T cells specific for that region relative to the virus 
at initial infection. Thus, in the setting of viral infection, the variant virus can exploit the relative 
hole in the T cell repertoire as an escape mechanism. This is the first example of a viral escape 
substitution resulting in evasion of the T cell response via exploitation of a hole in the T cell 
repertoire.  
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While substitution within T cell epitopes and the resultant loss of antigen may partially 
explain the decline of T cell responses generated to HCV in the acute phase of infection with 
progression to chronic infection, T cell responses to HCV epitopes that do not undergo 
substitution also decline. Additional evasion mechanisms must be employed to account for the 
decline observed when escape does not occur and the antigen is preserved. 
 
Mechanisms for evasion of T cell responses other than sequence variation 
Detectable levels of CD8 T cell recognition do not always result in escape substitutions 
and some CD8 T cell epitopes remain intact while others mutate within the same host (17,53). 
Reversion of immune-escape mutations after transmission to a new host suggests that immune 
escape can be associated with a significant cost to the virus in terms of fitness (43). It is therefore 
possible that some substitutions result in virus with such significantly reduced fitness that 
substitution at that position is not observed. With preservation of viral sequence, alternative 
mechanisms to evade T cell responses must prevail.  
 
T cell inhibitory receptors 
The growing family of inhibitory (or regulatory) receptors may be one of the most 
important categories of cell membrane receptors participating in the hyporesponsiveness of HCV 
specific T cells. Although many of these were initially identified on CD4 cells, their expression on 
CD8 cells has been documented and their engagement appears to inhibit CD8 effector function. 
One example is programmed death-1 (PD-1). PD-1 is an ITIM-containing inhibitory receptor 
expressed on activated T cells that binds two known ligands: PDL-1 (also called B7-H1) and PDL-
2 (also called B7-DC).(54-57). Anti-B7-H1/PDL-1 and anti-PD-1 antibodies partially restore 
activity in exhausted LCMV-specific T cells. PD-1 has recently been shown to be upregulated on 
HCV specific T cells and blockade of signaling through it to enhance their function (58-60). We 
found that surface PD-1 levels are significantly higher on HCV specific T cells in individuals who 
fail to control infection versus T cells from those who control infection in both early (<180 days) 
and later (>180days) infection.  Although multivariate statistical analysis indicated PD-1 levels on 
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HCV specific T cells are directly correlated with HCV RNA levels, high PD-1 levels are also 
associated with progression to chronic HCV infection independently of HCV RNA levels (61). Our 
comparative analyses of outcome of infection (clearance versus persistence) and PD-1 levels 
during acute infection demonstrate that PD-1 expression in HCV-specific T cells varies 
tremendously during acute infection and suggests that it is one of the independent determinants 
of outcome, a conclusion that bears relevance to intervention with blocking antibodies.  
 
Factors Associated with PD-1 Regulation 
In our statistical analysis, we determined that HCV RNA levels and outcome of infection 
are correlated with PD-1 levels, but not subject gender or age (61). Levels of PD-1 expression 
can also be dramatically affected by the presence versus absence of pro-inflammatory signals at 
the time of initial TCR engagement (62,63). In addition to inflammatory stimuli, the presence of 
antigen is necessary to maintain PD-1 expression. A recent study examining PD-1 expression on 
CD8 T cells specific from SIV infected macaques demonstrated that PD-1 expression gradually 
declined on CD8 T cells specific for an SIV-derived epitope that had undergone mutational 
escape (64).  We observed highly variable levels of PD-1 expression on tetramer+ HCV specific T 
cells during the chronic phase (>180 days infected) in patients who did not clear their infection. 
Despite the association between high HCV RNA levels and high PD-1 levels, we 
observed T cells with low PD-1 levels in the setting of high circulating HCV RNA levels, even at 
later time points once chronicity has been established. We performed serial viral sequence 
analysis in subjects and correlated with PD-1 levels on tetramer+ HCV specific CD8 T cells. Viral 
sequence was assessed at initial infection and at multiple subsequent time points at which T cells 
specific for known antigens were detectable. Where PD-1 levels decreased despite persistently 
high HCV RNA levels, we detected substitutions representing T epitope escape mutations in the 
circulating virus. In contrast, PD-1 levels remained high on virtually all of the T cells specific for 
HCV epitopes that did not undergo sequence substitution over the period of evaluation.  
Furthermore, restoration of intact antigen after escape was associated with an increase in PD-1 
levels (61). These results provide evidence that immune evasion mechanisms that allow HCV to 
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persist either involve epitope escape or alternatively, signals that maintain high expression of 
inhibitory “checkpoint” receptors on virus-specific T cells (Figure 1). Validation of this hypothesis 
requires defining the functional roles of these inhibitory receptors, which can in part be 
determined by assessing the effects of in vivo antibody blockade of the PD-1 and other inhibitory 
pathways. 
 
Durability and protective nature of hepatitis C immunity 
Although the vast majority of those infected will fail to clear hepatitis C virus, about 20-
30% of individuals will clear the virus spontaneously.  However, spontaneous control of HCV 
does not always result in sterilizing immunity. Reinfection with a new strain of HCV is possible 
and sometimes results in persistent infection. Re-infection provides another opportunity to query 
parameters of protective immunity. Sequential inoculation of convalescent chimpanzees over a 
period of 3 years with different HCV strains of proven infectivity resulted in viremic infection with 
the challenge virus (65). Control of a second HCV infection in chimpanzees that had previously 
controlled their initial HCV infection was kinetically linked to rapid acquisition of virus-specific 
cytolytic activity by liver resident CD8 T cells and expansion of memory CD4 and CD8 T cells in 
blood (35). The importance of memory CD8 T cells in control of HCV infection was confirmed by 
antibody-mediated depletion of this lymphocyte subset before a third infection. Virus replication 
was prolonged despite the presence of memory CD4 T cells primed by the two prior infections 
and was not terminated until HCV-specific CD8 T cells recovered in the liver. The same group 
also found that memory CD4 T cells are critical to long-term immunity by showing that antibody-
mediated depletion of CD4 T cells before re-infection of two immune chimpanzees resulted in 
persistent, low-level viremia despite functional intra-hepatic memory CD8 T cell responses (34). 
These experiments demonstrate an essential role for T cells in long-term protection from chronic 
hepatitis C. 
Demonstration of protective immunity following reinfection has been limited within 
humans due to the low incidence of re-infection and the stringent requirements for longitudinal 
follow-up. However, a recent study suggests that reinfection with subsequent persistent viremia 
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may not be uncommon (66). In two epidemiological studies that controlled for infection risk 
factors, individuals with previous clearance of HCV infection were less likely to develop infection 
than those infected for the first time and may have a lower risk of acquiring HCV despite ongoing 
exposure (67,68). Another study found long periods of undetectable viremia in subjects who 
cleared infection even in the setting of ongoing injection drug use (6).  To examine the hypothesis 
that protective immunity could be achieved in humans, we identified 164 people in the ALIVE 
cohort (69) who had no evidence of previous HCV infection and 98 individuals who had been 
previously, but were not currently, infected with HCV(68).  We compared the incidence and 
persistence of HCV viremia in these two groups over four consecutive 6-month periods. Of 
participants without previous infection, the incidence of HCV infection was 21%. By contrast, 
people previously infected were half as likely to develop new viremia (12%), even after 
accounting for risk behavior (hazard ratio, 0.45; 95% CI 0.23–0.88). Furthermore, in HIV-1-
negative people who developed detectable viremia, those previously infected were 12 times less 
likely than people infected for the first time to develop persistent infection (odds ratio 0.05, 95% 
CI 0.01–0.30), and the median peak HCV RNA concentration was two logs lower. These data 
suggest that immunity against viral persistence can be acquired, and that vaccines should be 
tested to reduce the burden of HCV-related liver disease. 
We have begun to investigate the cellular and humoral adaptive responses associated 
with protective immunity through examination of reinfected subjects. A major challenge in the 
study of HCV immunology in humans is the typically asymptomatic nature of acute HCV infection. 
We have in part overcome this barrier by longitudinally following injection drug users (IDU’s) at 
risk for infection and with ongoing HCV exposure following control of the initial infection. 
Sequencing of the virus allows us to identify infection with heterologous virus. These two factors 
permit identification of members of the cohort who have been re-infected and the opportunity to 
study the role of the immune system in long-term protection from chronic HCV. Between 1997 
and 2007, we identified 113 people who seroconverted with sufficient follow-up to evaluate 
outcome of infection. Reinfection occurred in 50% of those who controlled their first infection with 
variable virologic outcomes of subsequent infections. Although viral clearance occurs in 
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approximately 25% of patients with primary infections, spontaneous viral clearance was observed 
in 83% of reinfected patients. The incident reinfection rate in our group of cleared seroconverters 
was very similar to the incident primary infection rate previously reported in the same cohort (70); 
strongly suggesting that prior clearance of HCV infection does not provide sterilizing immunity 
against reinfection. However, the clearance rate of reinfection was almost reversed from the 
clearance rate of primary infection in our cohort, suggesting protection from chronic infection.  
Further evidence for the existence of protective immunity against HCV infection comes 
from analysis of infection kinetics during primary and re- infection. Frequent monitoring of HCV 
infection status allowed us to assess the kinetics of viremia during initial and subsequent 
infections within the same subjects.  The duration of viremia during primary infection was nearly 
four-fold longer than in subsequent infections in reinfected individuals. Similarly, the maximum 
concentration of HCV RNA detected in blood during reinfection was approximately three logs 
lower compared to initial infection even when persistent reinfections were included in the 
analysis. The lower duration and magnitude of viremia in the subsequent infections suggest that 
prior exposure to HCV provides protective immunity against persistent reinfection since fixed 
genetic factors associated with control of infection would not be expected to improve with each 
infection. 
 
Humoral immune responses during reinfection 
Because the appearance of neutralizing antibodies (nAb) corresponds with clearance of 
initial infections in some individuals (71), we investigated the role of nAb in control of reinfection. 
Given the absence of a culture system for circulating HCV strains, the capacity of serum 
antibodies to broadly neutralize HCV envelope protein binding and cell entry has been assessed 
using HCV pseudoparticles as previously described (71). During acute infection, nAbs against 
heterologous viral pseudoparticles were detected in 60% of reinfected subjects. Those nAb drive 
sequence evolution in the envelope regions of the virus, allowing escape of viral variants that 
negate neutralization (72). In contrast, cross-reactive nAbs are rarely detected in early infection in 
patients who progress to chronic infection (71). Compared with the initial infection, HCV 
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reinfection is associated with a reduction in the magnitude and duration of viremia, broadened 
cellular immune responses, and the generation of cross-reactive humoral responses. These 
findings are consistent with the development of adaptive immunity that is not sterilizing but 
protects against chronic disease. 
 
 
Figure 1 Viral evasion from the adaptive immune response 
The constraints placed on the virus due to immune pressure lead to clearance or select for 






Dissertation hypothesis: To investigate mechanisms through which HCV specific CD8+ T cell 
function is maximized, both through vaccine induction of responses and through understanding 
the relationship between sequence diversity and T cell regulation (activation and inhibition). In 
order to optimize T cell based vaccines against HCV, it is crucial to 1) select vaccine antigen that 
maximizes T cell function and cross reactivity and 2) reduce upregulation of T cell inhibitory 
molecules and promote effective memory T cell production.  
After writing a review of the mechanisms through which chronic HCV evades immune 
clearance, I focused on selection of vaccine antigens that enhance expansion of functional CD8 T 
cells against diverse HCV sequences. We suggest that the optimal CD8+ T response against 
HCV responds to a phylogenetically rooted ancestor. Mutations away from this sequence result in 
decreased or absent recognition as measured by cytokine functionality or surface receptor 
expression patterns. However, mutations that revert to the original sequence or sequences that 
structurally bind similarly to the HLA receptor will result in restoration of the optimal sequence 
recognition.I then sought to characterize the evolution of the CD8+ T cell response in the setting 
of absent, partial or incomplete, and complete recognition of HCV antigen. We have hypothesized 
that ongoing recognition of HCV antigen acts on the level of T cell receptor.  
 
Specific Aim 1:  
To determine whether a rational or computational approach to generate a T cell based vaccine 
would maximize T cell responses 
 
Approach: We assessed T cell recognition of potential hepatitis C virus vaccine sequences 
generated using three rational approaches: 1) combining epitopes with predicted tight binding to 
the major histocompatibility complex (MHC), 2) consensus sequence (most common amino acid 
at each position), and 3) representative ancestral sequence that had been derived using 
Bayesian phylogenetic tools. 
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Specific Aim 2: 
To determine the relationship between HCV-viral sequence changes and CD8+ T cell expression 
of co-inhibitory and activation surface molecules. 
 
Approach: 
CD8+ T cells were phenotyped using polychromatic flow cyometry to measure simultaneously the 
presence of activation and co-inhibitory molecules. Longitudinal viral sequence analysis was also 
performed to identify the circulating viral sequence prior to the onset of the adaptive immune 
response and throughout the course of infection after induction of T cell responses. The T cell 




In the United States, hepatitis C virus infects 4 million individuals and remains the leading 
cause of liver transplantation and hepatocellular carcinoma (2,3). The estimated morbidity 
associated with infection is anticipated to rise over the coming decade. Recent pharmacological 
advances promise interferon-free, direct acting anti-viral regimens with >90% achieving a 
sustained virological response and set to be licensed in the coming years (73-76). However, such 
treatment carries a high price tag, does not completely reverse HCV associated liver disease, and 
does not prevent reinfection. Thus, development of an HCV vaccine to prevent HCV infection 
remains a critical public health need despite the fact that no vaccine is currently available. 
Due in part to its highly error-prone NS5B polymerase, HCV circulates within and 
between individuals as a quasispecies (13). This swarm of viruses presents an immense 
challenge for vaccine development. Vaccine strategies meant to overcome this viral diversity 
must generate a broad immune response, capable of responding to a host of variations. Initial 
efforts at vaccine development focused on development of sterilizing immunity using an E1/E2 
heterodimer (77). Neutralizing antibodies against envelope can play a role in clearance of 
infection and re-infection (71,78,79). However, specific envelope sequences that drive broadly 
neutralizing antibody production and sterilizing immunity remain unknown. Generation of robust 
CD4+ and CD8+ T cell responses is considered critical for long-term immunity (19-21). 
Development of a cytotoxic T lymphocyte (CTL) response usually occurs early in infection and 
has a kinetic association with clearance of viremia (35). Failure of a CTL response to control 
viremia may be due to evasion of the T cell response through a number of mechanisms, including 
lack of CD4+ T cell help(41,80), T cell exhaustion(58,61,81,82), or the emergence of viral escape 
mutations (17,43,44,47,48,50,83). Although the cellular immune response to HCV declines in 
chronic infection, progressive broadening of the T cell response to HCV is associated with 
enhanced control of HCV upon repeated reinfection (78). The generation of cellular immunity 
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capable of controlling HCV infection analogous to that observed in people who successfully 
control repeated HCV infections has become a goal of HCV vaccine development(84).  
The T cell responses generated by a vaccine must provide cross-reactivity against highly 
diverse circulating strains, making selection of HCV vaccine antigens a challenge. Sequence 
strain selection to induce a T cell response, either for peptide or DNA-based vaccines, has 
borrowed heavily from HIV vaccine design (85,86). Strategies that deliver only a handful of 
epitopes or provide cross-coverage of multiple epitopes of a single HCV-protein may maximize 
recognition of that protein, but at the expense of other regions that may be important in protective 
immunity. Another strategy that has been shown to be effective for generating cellular immune 
responses using hepatitis B, lymphocytic choriomeningitis, and lassa virus vaccines in mice is 
selection of peptides with known high affinity for the major histocompatibility complex (MHC) (87-
89). High affinity binders may serve as a stronger immunogenic agent and peptides with high 
MHC affinity have been shown to be recognized by HBV and HIV infected humans and SIV 
infected macaques (90-92). However, the frequency of recognition of epitopes selected on the 
basis of MHC affinity for HCV is unknown. 
An alternative to the inclusion of specific epitopes that is commonly employed in vaccine 
strain selection is the use of a single circulating strain. The choice of which viral strain to use is 
arbitrary given that no circulating strain resembles the majority of other circulating strains of HCV. 
The extent to which any individual strain might have mutations that impair immune recognition 
and allow persistence is also unknown. Strain selection for HCV has focused on existing, well-
characterized strains, such as the genotype 1a strain H77 (93). HCV strains between subtypes 
can differ in nucleotide composition by 20-25% (94). By comparison, a less than 2% amino acid 
difference can cause a failure in cross-reactivity of the polyclonal response to influenza vaccine 
(85). An alternative to selection of specific epitopes or use of a single circulating variant is to use 
synthetic, computer-generated strains to minimize the degree of sequence dissimilarity between a 
vaccine strain and contemporary circulating viruses. There are multiple computational methods 
for generating a vaccine strain that minimizes the amount of sequence divergence (distance) 
between the antigen and contemporaneously circulating viruses. One method for artificial 
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sequence design is to create a consensus strain, whereby the most commonly predicted amino 
acid at each position is used at each position (85). A limitation of the consensus approach is that 
escape mutations can become the dominant sequence type in regions where the restricting HLA 
allele is common, as recently demonstrated for HCV (95). In contrast, phylogenetic reconstruction 
can distinguish residues with shared ancestry from those selected by individual hosts (96). We 
recently generated a representative synthetic HCV clone (bole1a) using Bayesian phylogenetic 
methods (97). This approach allowed calculation of the most probable base at each position 
using 390 HCV-1a sequences and an outgroup of HCV-1b sequences. While not naturally 
occurring, this strain’s sequence is similar to currently circulating HCV strains and lacks the 
divergent escape mutations carried by circulating strains. Therefore, bole1a may have enhanced 
ability to elicit robust, cross-reactive responses. However, the enhanced potential of any 
computer generated sequence to elicit cross reactive T cell responses has not been 
demonstrated for HCV. 
We assessed the recognition frequency and cross reactivity of HCV sequence peptides 
generated using the three vaccine development methods described: peptide selection based on 
high MHC binding capacity, selection of a single circulating strain, or use of the algorithmically 
derived representative bole1a sequence. We provide the first data in HCV to support the use of a 




The Baltimore Before and After Acute Study
 
of Hepatitis (BBAASH) cohort of injection 
drug users (IDU) is a prospective study of injection drug users at risk for hepatitis C infection. 
Eligible participants have a history of or ongoing intravenous drug use and are seronegative for 
anti-HCV antibodies at enrollment. Written consent was obtained from each participant. Once 
enrolled, participants receive counseling to reduce intravenous drug use and its complications 
(17). Blood is drawn for isolation of serum, plasma, and peripheral blood mononuclear cells 
(PBMC) in a protocol designed for monthly follow-up. Participants with acute HCV infection were 
 17 
referred for evaluation of treatment. The study was approved by the Institutional Review Board at 
the Johns Hopkins School of Medicine. 
 
Hemigenomic HCV sequencing: 
Total RNA was extracted from serum or plasma using the QIAmp viral RNA mini kit 
according to manufacturer’s directions (Qiagen). A 5.2kb region spanning the 5-untranslated 
region to the NS3/NS4A junction was reverse transcribed, amplified by nested PCR, and cloned 
as described previously(98). Briefly, total RNA was extracted from serum using the QIAamp viral 
RNA mini column (Qiagen) according to manufacturer’s instructions. The 5.2 kb PCR product was 
generated by a reverse transcription nested PCR strategy. Purified PCR products were cloned 
into a pCR-XL TOPO vector and transformed into One Shot TOP10 chemically competent cells. 
Forty clones were picked and amplified with Templiphi to screen for the presence of the insert. 
Positive clones were sequenced and aligned using CodonCode Aligner (Codon Code 
Corporation, Dedham, MA). 
 
Human Leukocyte (HLA) binding assay: 
Quantitative assays to measure the binding of peptides to purified class I molecules were 
based on the inhibition of binding of a radiolabeled standard peptide (99). Briefly, 1-10 nM of 
radiolabeled peptide was co-incubated at room temperature with 1 M to 1 nM of purified MHC in 
the presence of 1 M human 2-microglubulin (Scripps Laboratories, San Diego, CA) and a 
cocktail of protease inhibitors. After a two-day incubation, binding of the radiolabeled peptide to 
the corresponding MHC class I molecule was determined by capturing MHC/peptide complexes 
on Greiner Lumitrac 600 microplates (Greiner Bio-one, Longwood, FL) coated with the W6/32 
antibody, and measuring bound cpm using the TopCount microscintillation counter (Packard 
Instrument Co.). Alternatively, following the two-day incubation, the percent of MHC bound 




Generation of HCV genotype 1a consensus sequence (cons1a) 
Full-length genotype 1a polypeptide sequences (n=390) were downloaded from GenBank 
that were circulating in humans and were non-artificial sequences. Sequences were aligned to 
H77 and the consensus residues calculated with MargFreq program. 
 
Generation of HCV genotype 1a sequence (bole1a) 
Construction of the bole1a sequence has been described elsewhere (97). Briefly, the 
bole1a sequence was constructed using Bayesian phylogenetic and ancestral sequence 
reconstruction methods along with covariation analysis on the same set of 390 full-length 
sequences from which the consensus was derived. 
 
Cell culture to generate T cell lines: 
PMBCs were thawed and stimulated with 10ug/ml of synthetic peptide and 0.5ug/ml of 
anti-CD28 and anti-CD49d antibodies. Cells were maintained at a density of 2 x 10^6 cells/ml in 
RPMI 1640 [Sigma-Aldrich], 20% Human serum [Sigma-Aldrich], and 10mM HEPES buffer 
[Sigma-Aldrich] with 2 mM glutamine and 50 U/ml penicillin-streptomycin. Cells were incubated at 
37ºC and 5% CO2 with addition of rIL-2 on days 3, 4, 7, and 10 and again following a second 
round of peptide stimulation on day 10. 
 
Selection of epitope variant peptides and peptide synthesis: 
In subjects with detectable CD8+ T cell ELISpot responses against HCV, we examined 
the sequences of the epitope regions over time. When changes away from the consensus 
sequence occurred in the region of a CD8 T cell epitope, a synthetic peptides corresponding to 
that sequence as well as the consensus sequence were synthesized commercially by Genemed 
Synthesis (San Antonio, TX). 
 
Interferon-gamma ELISpot Assay 
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Ex vivo HCV CD8+ T cell responses were quantified by Human IFN gamma ELISPOT 
Ready-SET-Go!® assays (eBiosciences) according to manufacturer’s instructions. Briefly, PBMC 
were screened for recognition of HCV-specific antigens using pools of overlapping peptides 
covering the entire HCV polyprotein and previously defined optimal epitopes. Once responses 
were determined, additional analyses were performed using decreasing concentrations of 
synthesized peptides to determine the effects of amino acid substitutions on recognition and the 
degree to which there was cross-reactivity with circulating variants of the epitope and consensus 
sequence peptides  
To compare the magnitude of T cell responses generated in response to optimal and 
variant peptides, the same ELISpot assay was performed, using decreasing concentrations of 
synthesized peptides as antigen. Briefly, PVDF plates were coated with 2.5ug/ml recombinant 
human anti-IFN-gamma antibody (Endogen M-700A) in 100ul PBS/well at 37ºC at 4ºC overnight. 
Plates were washed with sterile PBS eight times before blocking with RPMI +10% FCS for 30 
minutes. Either 20,000 or 30,000 cells in R10 media were added to the wells. Decreasing peptide 
concentrations (10ul/well, 10ug/ml-0.001ug/ml) were added to the well in duplicate. PHA served 
as a positive control. Plates were incubated for 20 hours at 37ºC with 5%CO2. Following 
incubation, plates were washed with 200ul sterile PBS eight times and blotted dry. Biotin-labeled 
anti-IFN-gamma (Endogen, M-701B, 0.25ug/ml, 100ul) was added to each well and incubated for 
90 min at room temperature. Plates were washed and incubated with streptavidin-alkaline 
phosphatase (Bio-Rad 170-3554, 100ul) for 45 minutes at room temperature. Following additional 
washes, the plates were developed with BCIP/NBT Tris-buffer (pH 9.5) solution (Bio-Rad, 170-
6532 and 170-6539) according to manual instructions. Plates were dried overnight and read on a 
Ziess ELISpot plate reader. 
 
Statistical Analysis 
Statistical analysis was done using SigmaPlot software version 12.0 (Systat Software, 
Inc.). Log odds of frequency of recognition based on HLA matched subjects was calculated. 
Linear regression was performed on the log odds versus log of the IC50 from the in vitro binding 
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assay for HLA-matched sequences for positive responses in all subjects and among those that 
cleared acute infection. 
 
Results 
HLA binding affinity does not predict frequency of recognition. 
Peptides that bind strongly to the MHC can induce strong pathogen -specific immune 
responses in other chronic viral infections (90-92). As a result, selection of pathogen peptides 
with high MHC binding capacity has been used as a strategy in vaccine strain selection. In order 
to test the hypothesis that high affinity binding to Class I MHC is associated with increased 
frequency of HCV peptide recognition, the likelihood of recognition of previously identified class I 
restricted epitopes was correlated with the IC50 binding to its corresponding HLA allele and 
subtype. Our cohort is routinely screened during acute infection for responses against 
overlapping genotype 1a peptides, including both long regions of the HCV polypeptide and known 
class I epitopes (17). Assessment during the acute phase of HCV infection is critical since the 
breadth of HCV epitope recognition declines with progression to chronic infection (20,37). 
A total of 60 acutely HCV infected subjects had HLA genotype data available and were 
screened for HCV specific T cell responses to 35 epitopes with known HLA restriction and binding 
affinity (Table 1). To avoid spuriously negative results, the calculated frequency of responses 
against each known HLA-restricted epitope in the ELISpot assay includes data for only those 
subjects with matching HLA genotype and subtype. A positive response for a subject to any 
epitope was defined as recognition of that epitope in ELISpot testing at any time during infection. 
The frequency of recognition varied widely between epitopes. For example, we found that nearly 
half of HLA-A*0201 individuals (14/33, 42%) recognized the HLA-A*02-restricted epitope NS3 
1406-1415 (KLVALGINAV) (Table 1). In contrast, 13/35 (37%) of the tested epitopes were never 
recognized despite being restricted to 23 different HLA subtypes present in 54 different subjects 
tested. To determine if recognition frequency was correlated with HLA-binding affinity, affinity and 
recognition frequency were compared. 
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An in vitro competitive binding assay of peptide to the restricting HLA allele was used to 
assess the strength of binding to the MHC (Table 1), with some of these results reported 
previously (100,101). This assay measures HLA binding affinity of test peptides by determining 
the concentration of test peptide required to inhibit by 50% binding of radiolabeled peptides to 
purified HLA molecules of known subtypes. Requiring high concentrations of test peptide to 
compete with binding of the radiolabeled peptide to the restricting MHC (high IC50) suggests low 
affinity for that HLA molecule. We compared the frequency of epitope recognition among HLA-
matched individuals to the inhibitory concentration in the in vitro HLA binding assay, and found no 
significant relationship (Figure 2A). For all subjects and responses, HCV peptides with higher 
HLA binding affinity were no more likely to be recognized than those with low binding affinity (y=-
0.1254x-0.4992, r
2
=0.0492, OR=0.882, 95%CI 0.69-1.12). Moreover, 12/19 (63%) high affinity 
HCV peptides (IC50 <50nM) were never recognized at any time point examined in our large 
cohort of acutely HCV infected subjects. This lack of relationship between frequency of 
recognition and HLA binding affinity held even when we examined the subset of subjects who 
cleared acute infection and therefore had successful immune responses (Figure 2B, y=-0.1464x-
0.2524, r2=-0.0925, OR=0.866, 95% CI=-13.0-12.7). Having found no association between HLA 
binding affinity and T cell recognition, we evaluated immunogenicity of vaccine strains generated 
in alternative ways.  
 
Bole1a sequence induces more robust responses than consensus sequence. 
The use of consensus or representative sequences has been proposed in vaccine design 
to minimize the genetic differences between vaccine strains and contemporary isolates. A 
consensus sequence includes the most common amino acid at each position. However, such a 
sequence is subject to the frequencies of common HLA alleles in the population and the forces by 
which these alleles shape circulating viral sequence. Evolutionary forces on the population level 
due to common HLA alleles play a contributory role on the frequency of circulating escape 
variants (95,96). The methods used to generate bole1a minimized the genetic distance from 
circulating sequences while maximizing the likelihood that selected residues represented 
 22 
universally-shared (i.e. rather than individual) evolutionary forces. For comparison, we used the 
same 390 full length genotype 1a HCV polypeptide sequences that were used to construct bole1a 
to generate a consensus sequence (cons1a). Bole1a sequence contains a larger number of 
known T cell epitopes than do the H77 and HCV-1 strains (97) despite H77 and HCV-1 having 
been used widely to identify HCV epitopes. Bole1a is less likely to contain escape mutations that 
would impair T cell recognition (85). The cons1a and bole1a sequences were compared for 
homology across 15 epitopes located between Core and NS3. For 13/15 epitopes, the sequences 
were identical with the two exceptions noted in Table 2. In general, the consensus amino acid 
residue was clearly defined, with 90% or higher frequency of a single residue. Where the 
consensus amino acid differed from bole1a, the frequency at the differing position was between 
0.405 and 0.523. 
T cell recognition of artificial HCV sequences has not yet been demonstrated. Therefore, 
we initially sought to determine if the artificially generated HCV vaccine sequences cons1a and 
bole1a could induce robust T cell responses and if the sequences differed in their capacity to do 
so. The cons1a and bole1a sequences were tested for their capacity to expand T cells already 
primed in vivo against circulating HCV. Lines were generated against peptides encoding the two 
cons1a and bole1a sequences that differed and then tested for recognition of both the cons1a 
and bole1a sequences by IFN-gamma ELISpot (Figure 3A and 3B). In both cases, the bole1a 
sequence peptides were able to expand T cell responses that recognized bole1a and consensus 
sequences for that epitope. In contrast, incubation with the consensus sequence expanded T 
cells well for only one of the two epitopes. Expansion with consensus NS3 1436-1444 (ATDALMTGF) 
resulted in minimal recognition of either variant of that epitope (Figure 3A). Expansion with 
consensus E2610-618 (HYPYRLWHY) recognition of both variants, but of much lower magnitude 
than that achieved with bole1a sequence expansion (Figure 3B). Overall, T cells expanded with 
the bole1a sequence-encoded peptides had greater magnitude responses against both bole1a 
and consensus sequences than those sequences expanded with cons1a (Figure 3C). Given the 
improved expansion using bole1a compared to cons1a, future comparisons of the 
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immunogenicity of artificial strains to circulating HCV strains were completed using bole1a 
sequence for these epitopes. 
 
Bole1a sequence better expands CD8+ T cells of diverse HCV specificity 
Mutation within CD8+ T cell epitopes occurs frequently, with 69% of epitopes undergoing 
mutation in the first six months of infection(17). We and others have previously demonstrated 
selection of and subsequent dominance of HCV variants that evade neutralizing antibody and 
CD8+ T cells responses (17,71,102). Thus, any given circulating HCV strain from an individual is 
likely to contain a large number of escape mutations that allow evasion of T cell recognition 
(44,103). The capacity of a vaccine strain to induce CD8+ T cell responses to naturally occurring 
sequence variants will likely be reduced if the vaccine strain used contains escape mutations.  
Naturally occurring HCV variants within epitope regions were identified through 
longitudinal hemigenomic sequencing of HCV from subjects (Table 4) who recognized CD8+ T 
cell epitopes of known HLA-restriction. Identified amino acid substitutions within these epitopes 
are listed in Table 3. Bole1a and consensus sequences were identified in circulating sequences 
for all epitopes investigated, confirming that sequences algorithmically chosen are also found in 
natural infection. 
Given that representative HCV strains should contain fewer escape mutations than do 
naturally circulating strains, we hypothesized that CD8+ T cells already primed in vivo against 
HCV would better recognize bole1a sequence than any individual circulating strain. Expansion 
capacity of the bole1a sequence relative to naturally occurring sequence variants was tested. 
Lines were generated against peptides encoding the bole1a sequences or naturally circulating 
sequence variants. These lines were tested for recognition of the bole1a sequence and the 
corresponding naturally occurring sequence variants using peptide dilutions in an IFN-gamma 
ELISpot assay (Figure 4A-G). Lines were successfully generated against 8/8 (100%) peptides 
encoding bole1a sequences and for 12/18 (67%) peptides derived from naturally occurring 
sequence variants that did not match bole1a (Figure 4A-G and Figure 3A and B). Incubation of T 
cells with every naturally occurring sequence variant of the Core41-49 epitope (Figure 4A) as well 
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as three of the four NS31073-1081 (Figure 4F) epitopes failed to generate any ELISpot responses 
above background to bole1a or sequence variant antigen peptides. This suggests that the 
naturally occurring variants of these epitopes are less able than bole1a to expand cross reactive 
T cell responses. In addition, when expansion of T cells with naturally occurring sequence 
variants did occur, the responses were of diminished magnitude relative to those obtained using 
the bole1a sequence to expand. The single exception occurred for p7 790-790, where expansion 
with either the bole1a sequence or a naturally occurring sequence variant produced comparable 
(within 2-fold) recognition of both sequences across four of five peptide dilutions (Figure 4E). 
Figure 4H shows the summation of ELISpot responses against 10, 1, and 0.1uM of the bole1a 
and every variant peptide for each epitope when bole1a is used to expand (left column) or a 
naturally occurring variant is used to expand (right column). For 6/7 (86%) epitopes, expansion 
with bole1a sequence resulted in stronger summed responses against itself and sequence 
variants as measured by total SFC per million cells than did expansion with circulating variants 
(Figure 4H). The single exception, the p7 790-790 sequence, still resulted in an overall strong 
magnitude of response against both the bole1a sequence as well as the naturally occurring 
sequence variant. Thus, bole1a best or comparably expands T cells specific for HCV epitopes, 
again supporting the superiority of the bole1a sequence over circulating variants in expanding T 
cell responses broadly specific for HCV.  
 
Bole1a sequence expands T cells of diverse cross-reactivity. 
The level of cross-reactivity for seven epitopes was compared across individuals to 
determine if recognition patterns were consistent across subjects and if bole1a expanded T cells 
specific for variants not seen in that subject. We tested our CD8+ T cell lines against the 
indicated bole1a sequence for recognition of all the epitope variant peptides identified in our 
sequencing of circulating HCV strains as well as bole1a and consensus sequence epitopes 
(Figure 5A-G, Table 3, Table 5). The bole1a sequence was recognized by all subjects and for 
every epitope at least the two highest concentrations of peptide. However, the recognition 
patterns for specific variants did vary between subjects and by epitope. For example, expansion 
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of T cells with either the peptide encoding bole1a sequence for the epitope NS31436-1444 or its 
variant resulted in similar recognition patterns of bole1a and the variant sequence (Figure 5A) 
between subjects. In other cases, expansion with bole1a-encoded sequence resulted in better 
recognition of the bole1a sequence than any variant, but with differing recognition profiles of 
variant sequences (5B-D). Finally, expansion with bole1a-encoded sequence resulted in equal 
recognition of sequence variants and itself for three epitopes (Figure 5E-G), although the extent 
of variant recognition differed across subjects. T cells expanded from both subjects recognized 
the D610H and D610N variants well with diminished recognition of the other three sequence 
variants (Figure 5E). These results suggest that expansion of T cells with bole1a is likely to 
generate T cell responses that recognize many different circulating HCV variants in different HCV 
exposed subjects. In contrast, expansion with any given circulating variant results in widely 
different levels of recognition depending on the subject and HCV exposure. 
 
Bole1a sequence contains the greatest number of optimal epitopes. 
Following vaccination against any virus, individuals subsequently exposed to that virus 
will have to respond to a multitude of sequences similar but not identical to those they have 
already seen. Optimal sequences, or those sequences that stand the greatest likelihood of being 
cross-reactive in a vaccine, were defined as sequences that a) induce a response when used to 
generate a line and b) induce maximal responses. For a given epitope position, the optimal 
sequence was defined experimentally as the sequence that induced the greatest recognition on 
IFN-gamma ELISpot at a peptide concentration of 1uM. Lines generated that produced only 
responses less than 100 SFC/1E6 cells were excluded from consideration. Of the ten epitopes 
assessed, six had a single optimal sequence. For four epitopes, two sequences were equally well 
recognized with responses of a magnitude within two-fold of the strongest response. When two 
sequences produced comparable responses, both were deemed optimal. For example, the 
WPAPQGARSL and WPAPQGSRSL variants of the NS31111-1120 epitope were comparably 
recognized in multiple ELISpot assays across multiple individuals so both were accepted as 
optimal sequences. 
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The presence of the optimal sequence or sequences for the ten epitopes tested was 
assessed across the 390 full length genotype 1a sequence culled from GenBank as well as the 
bole1a and cons1a sequences. The tabulated data are presented in Figure 6. Bole1a was found 
in the group of sequences containing the highest number of optimal epitopes and contains 
optimal sequence for every of the ten epitopes. Twenty nine other viral strains also contained all 
of the optimal sequences. In comparison, the cons1a and the H77 sequence were found to 
contain only 9/10 optimal epitopes despite the H77 strain being used to define most of the known 
HCV epitopes.  
 
Discussion 
Successful vaccination strategies against extremely genetically diverse viruses like HCV 
will require generation of an immune response that is both broadly cross-reactive and robust 
against the antigens to which vaccine recipients are subsequently exposed. Significant 
controversy exists about the best method for selection of a vaccine strain capable of inducing 
strong, cross-reactive T cell responses against divergent circulating strains. Clinical trials in 
humans comparing the capacity of different vaccines to induce protective responses are not 
possible due to expense and limited access to those at risk for infection. Thus, surrogate 
measures for vaccine strain efficacy are needed. We elected to focus on HCV genotype 1a 
infectious strains as the most common infectious subtype in the US as well as one of the most 
difficult to eradicate by therapy. This study presents a comprehensive analysis of the efficacy of a 
computationally designed genotype 1a HCV sequence (bole1a) to expand HCV specific T cell 
responses relative to a consensus sequence or individual circulating strains as well as an 
assessment of the relationship between HLA binding affinity and recognition. 
Beginning with the method of selecting peptides with high HLA binding affinity as vaccine 
antigens, we assessed the frequency of peptide recognition relative to HLA binding capacity. If 
peptides bound more strongly to the MHC induce recognition more frequently, those peptides 
might be better candidates for a vaccine sequence. For hepatitis B, lymphocytic choriomeningitis, 
and HIV, high affinity peptides have been proposed as vaccine antigens based on their enhanced 
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immunogenicity (87,89,91). However, we found no association between HCV peptide binding to 
the MHC and frequency of recognition in an acutely infected HCV cohort. The lack of association 
also held among those who clear infection, suggesting that the strength of binding to the MHC 
does not predict likelihood of developing an effective HCV response. High HLA binding affinity as 
a method for producing antigen has been proposed in previous studies (100), (101). To evaluate 
this strategy, a previous study assessed the capacity of peptide with high HLA A*02 binding 
affinity to prime naïve T cell responses in vitro using human cells and in vivo in mice. While some 
peptides were capable of inducing responses in both models, it remained unclear from that study 
if in vivo priming of HCV specific T cells favors recognition of high affinity HLA binders (100). Our 
study compares in vivo human recognition of peptide epitopes restricted to multiple HLA alleles 
with widely diverse binding capacity. Another study proposed the use of high HLA binding affinity 
with ability to bind multiple alleles to select HCV vaccine antigen and found that peptides with 
comparable HLA binding capacity could have markedly different immunogenicity (101). This is 
supportive of our study’s finding that HLA affinity beyond that needed to bind was not the major 
determinant of recognition. Once MHC binding beyond a relevant threshold is achieved, other 
factors such as location of the epitope in the polypeptide, its abundance, thymic education, and T 
cell precursor frequency appear to play a dominant role in selecting the actual epitope recognized 
(104,105). 
The most commonly proposed method in vaccine design for HCV is selection of an 
individual circulating sequence. However, any individual circulating sequence is likely to contain 
escape mutations that result in diminished T cell recognition relative to those generated against 
the initial infecting sequence(17) or a prototype sequence (106,107). Bole1a is designed to 
decrease the genetic distance between vaccine and circulating strains and to minimize the 
inclusion of escape mutations. Although the consensus sequence had shared identity for 13/15 
epitopes, our head-to-head comparison of cons1a versus bole1a sequence at the two epitopes 
that differed demonstrated improved capacity to expand cross reactive HCV specific T cells 
responses using bole1a. One of the differences present in the consensus sequence represented 
a known escape mutation in an HLA A*01 restricted epitope. The HCV NS31436-1444 ATDALMGY 
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epitope has been shown to predominate in HLA A*01 populations, despite a known fitness cost 
(95). 
Following vaccination against any virus, individuals subsequently exposed to that virus 
will have to respond to sequences similar but not identical to those they have already seen. Ability 
to expand T cell populations that recognize common circulating sequence variants will be critical 
if any individual sequence is used as a vaccine strain. Bole1a reliably expanded T cell responses 
against a broad array of circulating variants with greater magnitude of responses compared to 
naturally occurring sequence variants (Figure 4H). The bole 1a sequence can induce cross-
reactive responses against many variants, including those not circulating in that host; an 
observation noted across subjects.  
Although bole1a expanded T cells capable of recognizing many different circulating 
epitopes, some circulating variants were not recognized well by T cells expanded with any 
peptide sequence. For example, for the CINGVCWTV bole1a HCV NS31073-1081 peptide epitope, 
three of the four circulating variants of that sequence (CINGACWTV, CINGECWTI, and 
CINGECWTV) are very poorly recognized regardless of the peptide variant used to expand T 
cells(Figure 4F). Vaccination with any sequence is unlikely to induce a response to those 
sequences. Variant sequences have been shown to escape the T cell response through a 
number of mechanisms, including decreased binding to the MHC (44) or exploitation of a hole in 
the repertoire (52). How many T cell epitopes must be recognized to generate an effective T cell 
response is unknown. Thus, the impact of failure to generate a response to any one viral epitope 
is unclear. However, failure to generate a single T cell response is unlikely to render a vaccine 
ineffective. 
Compared to T cells expanded with bole1a, T cell expansion with naturally occurring 
HCV variants generally resulted in diminished recognition of circulating sequence variants. While 
some variant sequences produced cross-reactive responses, others induced no cross-
recognition. In addition, some variant sequences failed to induce any T cell response, making 
selection of a naturally circulating sequence problematic. 
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Bole1a contains a larger number of epitopes in the Immune epitopes database than did 
any circulating strain of HCV assessed (97). Experimentally, bole1a and 29 other sequences 
contain 10 of the 10 epitope sequences tested that were deemed most optimal for expansion and 
recognition, outperforming both cons1a and H77. The difference might have been greater had a 
larger number of epitopes been assessed. The H77 sequence contained nearly as many with 9 of 
the 10 optimal epitopes. This is not surprising given that H77 has been the most commonly used 
sequence for epitope discovery. Many of the tested epitopes were derived from this sequence in 
the generation of peptides to screen for T cell responses. Given the historical reliance on H77 for 
epitope identification, that bole1a contained even more optimal epitopes supports its use. In 
addition to the experimentally observed reliable expansion of cross-reactive, robust T cell 
responses, this theoretical assessment of immunogenicity also argues for the use of a 
representative sequence like bole1a. 
The HIV literature debate over HIV strain selection has suggested use of multiple 
reference sequences, consensus sequences (85), most recent common ancestor sequence, or 
mosaic sequences. The STEP trial used gag, pol, and nef sequences from three reference strains 
in an Ad5-based vaccine and failed to reduce the incidence of infection, to lower HIV RNA set 
points (108), or to induce a difference in CD8+ T cell responses (109). Part of this failure has 
been attributed to the immunogenicity of the Ad5 vector in prime and boost, but selection of 
reference strains may also play a role. Vaccination of macaques has not found a consensus 
sequence to be particularly immunogenic compared to alternative methods (110). However, 
immune pressure on HIV is intense and consensus sequence contains escape mutations as a 
result. For example, the frequency of HIV variants in HLA B*57, HLA-B*27, and HLA-B*51 
restricted sequences has been correlated with the prevalence of the restricting allele in 
populations, suggesting an evolving relationship between HIV sequence and HLA frequency 
(111). Finally, the use of computer generated sequences in vaccine design has been proposed 
for HCV (112) with coverage compared to reference strain H77, but direct testing of 
immunogenicity and cross-recognition had not been demonstrated previously. Our study provides 
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the first evidence that a computer generated HCV sequence can both expand cross reactive T 
cell responses and be recognized as antigen.  
There are some limitations to our study. Lines generated against a sequence offer insight 
into recognition of sequence variants but may artificially expand one subset of the polyclonal 
population in a way that would not occur in vivo. In addition, we did not examine sequence cross-
reactivity in multiple genotypes due to a relative infrequency of non-genotype 1 infections in our 
cohort. However, certain epitopes and escape variants are conserved across genotypes. For 
example, the escape variant Y1444F is the same variant in genotypes 1a, 1b, and 3a infection 
(95). Thus, our results may be relevant in non-genotype 1 infections. We are also limited to 
assessing responses that appear in the peripheral blood. Other studies have implicated an 
increased breadth and frequency in the CD8+ T cell response in the intrahepatic compartment 
versus the peripheral response (26,106). Thus, we may have underestimated the frequency of 
responses detected. Furthermore, we were unable to assess HLA-binding affinity for all known 
epitopes, including those of HLA-C as well as the B*27 and B*57 alleles. The presence of either 
the B*27 or the B*57 allele in HCV infected subjects is associated with increased frequency of 
HCV clearance (113). 
We also demonstrate capacity to expand from previously HCV-exposed individuals rather 
than immunogenicity in HCV uninfected subjects. Ideally, vaccination of naïve hosts with every 
variant and artificial sequence would be performed. The assessment of the subsequent immune 
response would allow a more accurate comparison of immunogenicity. Given the lack of 
feasibility of such experiments, we assessed capacity to expand and cross-reactivity as a 
surrogate. 
In conclusion, generation of a successful T cell vaccine will require a strain that is 
immunogenic as well as cross-reactive within genotype, or even better, with multiple genotypes. 
We have demonstrated for the first time the efficacy of a synthetic representative sequence, 
bole1a, to expand a robust and cross-reactive CD8+ T cell response and its superiority over other 
strategies. We anticipate that this strategy will help direct vaccine sequence selection for hepatitis 
C infection. 
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Table 1 HLA binding affinity and frequency of recognition of peptides.  
Synthesized peptides encoding known HCV epitope sequences were tested in an in vitro 
radiolabeled competitive binding assay for binding to the MHC, and the 50% inhibitory 
concentration (IC50, nM) was determined. BBAASH subjects (n=60) with known HLA typing were 
screened at acute and chronic time points for responses against overlapping HCV peptides in an 
IFN-gamma ELISpot. Frequency of recognition of HLA restricted peptide epitopes by subjects 
with the matched HLA allele and subtype was determined. Subjects lacking the HLA allele 
required for presentation were excluded. Fraction recognition was calculated as follows: fraction 
recognition = (number of subjects with matched HLA allele recognizing epitope)/(total number of 






















YLLPRRGPRL 35 A*02:01 125 0 33 0 
GPRLGVRAT 41 B*07:02 15 5 15 0.33 
RLGVRATRK 43 A*03:01 12 0 16 0 
RLGVRATRK 43 A*11:01 6 0 5 0 
RLGVRATRK 43 A*31:01 429 0 3 0 
KTSERSQPR 51 A*03:01 69 0 16 0 
KTSERSQPR 51 A*11:01 38 0 5 0 
KTSERSQPR 51 A*31:01 67 0 3 0 
DLMGYIPLV 132 A*02:01 80 3 33 0.09 
LLALLSCLTV 178 A*02:01 357 1 33 0.03 
FLVGQLFTF 285 A*02:01 67 1 33 0.03 
RLWHYPCTI 614 A*02:01 23 7 33 0.21 
RLWHYPCTV 614 A*02:01 12 11 33 0.33 
RMYVGGVEHR 630 A*03:01 15 1 16 0.06 
RMYVGGVEHR 630 A*11:01 8 0 5 0 
RMYVGGVEHR 630 A*3101 95 0 3 0 
LEDRDRSEL 654 B*40:01 426 1 3 0.33 
LEDRDRSEL 654 B*40:02 4267 1 2 0.50 
HPALVFDIT 881 B*07:02 160 1 15 0.07 
RPALVFDIT 881 B*07:02 43 0 15 0 
CINGVCWTV 1073 A*02:01 55 13 33 0.39 
CTCGSSDLY 1123 A*0101 108 0 12 0 
YLVTRHADV 1131 A*02:01 454 0 33 0 
TLGFGAYMSK 1261 A*03:01 124 0 16 0 
LGFGAYMSK 1262 A*03:01 136 0 16 0 
LGFGAYMSK 1262 A*11:01 21 0 5 0 
GIDPNIRTGV 1273 A*02:01 722 3 33 0.09 
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GVDPNIRTGV 1273 A*02:01 351 1 33 0.03 
HPNIEEVAL 1359 B*35:01 99 1 5 0.20 
HPNIEEVAL 1359 B*35:03 6.8 1 3 0.33 
IPFYGKAI 1377 B*07:02 497 0 15 0 
HSKKKCDEL 1395 B*08:01 764 7 13 0.54 
KLVALGINAV 1406 A*02:01 5 14 33 0.42 
ATDALMTGY 1436 A*01:01 1.3 5 12 0.42 
SLMAFTAAV 1789 A*02:01 26 3 33 0.09 
LLFNILGGWV 1807 A*02:01 4 0 33 0 
ILAGYGAGV 1851 A*02:01 116 0 33 0 
GVAGALVAFK 1858 A*03:01 26 0 16 0 
GVAGALVAFK 1858 A*11:01 4 0 5 0 
VAGALVAFK 1859 A*03:01 46 0 16 0 
VAGALVAFK 1859 A*11:01 7 0 5 0 
VLSDFKTWL 1992 A*02:01 305 6 33 0.18 
DVVCCSMSY 2415 A*26:01 25 0 2 0 
RLIVFPDLGV 2578 A*02:01 56 4 33 0.12 
RVCEKMALY 2587 A*03:01 56 2 16 0.13 
GLQDCTMLV 2727 A*02:01 18 3 33 0.09 
SLLAPGAKQNV 4091 A*02:01 513 1 33 0.03 
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Table 2 Bole1a and consensus sequences.  
Bole1a and cons1a sequences were compared for identity for known MHC class I restricted 
epitopes. The two epitopes for which bole1a (top) and the consensus (bottom) sequence differ 
are shown with the frequency of each amino acid at each position. 
 
HLA  A.A. Location  Sequence  
C*07 E2 610-618 
D Y P Y R L W H Y 
 
0.331 0.997 0.897 1 1 0.995 1 1 0.992 
 
H 
         
0.405 
         
A*01 NS3 1436-1444 
A T D A L M T G Y 
 
0.992 1 1 1 1 1 1 1 0.477 
 
        
F 
 





Table 3 Bole1a and Identified Variant Sequences 
Subjects who recognized known epitope peptide sequences in an overlapping peptide ELISpot 
screen were followed longitudinally for sequence changes within the epitope region. Amino acid 
sequences for bole1a-encoded sequences with their positions in the HCV polypeptide and HLA 
restriction re written in full and are in bold with naturally occurring identified sequence mutations 
identified underneath by their changes away from the bole1a sequence. 
HCV protein A.A. Location Peptide HLA restriction 
Core 1-9 MSTNPKPQKK A*11 
    ---D----R-   
    --------R-   
    --------RQ   






     -------T-   
E1 285-293 FLVGQLFTF A*02 
    ------L--   
    ---S-----   












     N--------   
E2 614-622 RLWHYPCTI A*02 
    --------A   
    --------T   
    --------V   
E2 621-628 TINYTIFK A*11 
    -------R   
E2 654-662 LEDRDRSEL B*60 
    -----K-K-   
p7 790-799 LYGMWPLLLL A*29/C*07 
    F---------   
NS2 957-964 RDWAHNGL B*37 
    -N---S-L   
    -S---DS-   
    -S----S-   










     --------I   
NS3 1111-1120 WPAPQGARSL A*26 
    -A----S---   
    ------S---   
NS3 1359-1367 HPNIEEVAL B*35 
    -S-------   









     ---R-----   
NS3 1406-1415 KLVALGINAV A*02 
    --G-M-----   
    ---G-V----   
    ----M-----   
    --T-------   
    ---T------   
    ------V---   
    ---V--V---   
NS3 1436-1444 ATDALMTGY A*01 




Table 4 HLA types of subjects in whom naturally occurring sequence variants were 
identified. 
Cohort ID HLA A1 HLA A2 HLA B1 HLA B2 HLA C1 HLA C2 
17 *02:01 *03:01 *35:03 *51:01 *04:01 *14:02 
18 *02:01 *02:01 *55:01 *44:03 *03:03 *04:01 
24 *02:01 *03:01 *07:02 *57:01 *06:02 *07:02 
26 *02:01 *11:01 *35:01 *52:01 *12:02 *15:02 
28 *01:01 *02:01 *08:01 *37:01 *06:02 *07:01 
29 *01:01 *02:01 *08:01 *13:02 *06:02 *07:01 
30 *01:01 *02:01 *08:01 *08:01 *07:01 *07:02 
45 *02:01 *02:02 *14:02 *15:16 *44:02 *05:01 
46 *01:01 *03:01 *07:02 *08:01 *07:01 *07:02 
47 *11:01 *32:01 *35:01 *40:02 *04:01 *15:02 
49 *02:01 *30:04 *49:01 *51:01 *02:02 *07:01 
50 *02:01 *24:02 *44:02 *51:01 *01:02 *05:01 
51 *02:01 *02:01 *45:01 *51:01 *14:02 *16:01 
52 *01:01 *01:01 *08:01 *08:01 *07:01 *07:01 
53 *02:01 *30:01 *13:01 *37:01 *06:02 *06:02 
57 *02:01 *02:01 *07:02 *15:01 *01:02 *07:02 
109 *03:01 *03:01 *07:02 *08:01 *07:01 *07:02 
111 *01:01 *26:01 *08:01 *51:01 *07:01 *15:02 
113 *01:01 *02:01 *07:02 *08:01 *07:01 *07:02 
115 
a a a a a a 
116 *02:01 *24:02 *39:06 *57:01 *06:02 *07:02 
133 *29:02 *31:01 *44:02 *51:01 *05:01 *14:02 
139 *02:01 *11:01 *35:01 *52:01 *12:02 *15:02 
145 *02:01 *02:01 *40:01 *44:05 *02:02 *03:04 
148 *02:01 *02:01 *07:02 *44:03 *07:02 *16:01 
154 *24:02 *31:01 *07:02 *51:01 *01:02 *07:02 
160 
a a 
*44:02 *44:03 *05:01 *16:01 
171 *23:01 *33:03 *15:03 *53:01 *02:10 *04:01 
175 *02:01 *03:01 *07:02 *15:01 *03:04 *07:02 
177 *02:01 *30:02 *18:01 *40:01 *03:04 *05:01 
181 
a a a a a a 





Table 5 Epitope sequence data from subjects from whom T cell lines were derived.  
Bold indicates visit at which T cell lines were used. 
Subject Duration of infection (days) Epitope Sequence 
18 16 E2614-622 RLWHYPCTI 
 97  n.d. 
 202  --------- 
 521  --------- 
 1158  --------V 
 1499  --------V 
18 16 E2621-628 TINYTLFK 
 97  n.d. 
 202  -------- 
 521  -------- 
 1158  -V---I-- 
 1499  -V---I-- 
18 16 NS31073-1081 CINGVCWTV 
 97  n.d. 
 202  --------- 
 521  --------- 
 1158  --------- 
 1499  --------- 
18 16 NS31111-1120 WPAPQGARSL 
 97  n.d. 
 202  ---------- 
 521  ---------- 
 1158  ------S--- 
 1499  ------S--- 
18 16 NS31406-1415 KLVALGINAV 
 97  n.d. 
 202  ---------- 
 521  ---------- 
 1158  ---------- 
 1499  ---------- 
26 15 NS31406-1415 KLVALGINAV** 
   ------V---** 
 104  KLVALGINAV 
65 16 NS31436-1444 ATDTLMTGY 
 379  ----A---F 
 702  ----A---F 
 1030  ----A---F 
 2374  n.d. 
109 539 Core41-49 * 
 726  GPKLGVCAT 
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 993  --R---RT- 
109 539 E2610-618 * 
 726  DYPYRLWHY 
 993  --------- 
109 539 E2621-628 * 
 726  TINYTIFR 
 993  -------- 
109 539 p7790-799 * 
 726  LYGMWPLLLL 
 993  ---------- 
109 539 NS31111-1120 * 
 726  WAAPQGSRSL 
 993  ---------- 
109 539 NS31395-1403 * 
 726  HSKKECDEL 
 993  ---R----- 
113 18 NS31436-1444 ATDALMTGY 
 57  --------F 
 81  --------F 
 114  n.d. 
148 608 E2610-618 n.d. 
160 140 NS31073-1081 CINGACWTV 
 251  ----V----** 
   ---------** 
 308  --------- 
 462  ----V---- 
 650  --------- 
 677  --------- 
 719  --------- 
181 221 NS31395-1403 n.d. 
*aviremic 
** both sequences present 
n.d. = no data 
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Figure 2 Lack of correlation between HLA binding affinity and frequency of recognition 
The frequency of epitope recognition among 60 HCV infected subjects with matching HLA allele 
and subtype was assessed. HLA binding affinity was determined in an in vitro assay using 
purified HLA molecules with known allele and subtype. The percent of subjects recognizing HLA-
matched epitopes as derived in Table 1 was graphed relative to the HLA binding affinity for (A) all 




Figure 3 Relative to bole1a peptides, consensus peptides fail to or poorly expand T cells 
specific for peptides from either sequence. 
PBMC were stimulated for twenty days with peptides bearing either the bole1a or consensus 
cons1a sequences. Stimulating peptide sequence is indicated on each graph in the upper right 
corner. The resulting lines were tested against titrated concentrations of peptides encoding the (--
•--) bole1a or cons1a sequence (--о--) in duplicate wells. (A) HLA A*01 HCV NS3 1436-1444, 
subject 65 (B) HLA C*07 HCV E2 610-618, subject 109 (C) Summation of the total magnitude of 





Figure 4 Relative to peptides encoding bole1a sequence, peptides encoding variant 
sequences fail to or poorly expand T cells specific for either bole1a or variant sequence. 
PBMC were stimulated for twenty days with a peptide of either the bole1a or an identified 
circulating sequence of that same epitope. In the upper right corner of each graph, the sequence 
used to expand is shown with amino acid differences from bole1a underlined. The resulting lines 
were tested against titrated concentrations of peptides in duplicate wells encoding the bole1a 
sequence (--•--) and all identified circulating variants of that epitope (open shapes) in an IFN-
gamma ELISpot assay. (A) HLA B*07 HCV Core 41-49, Subject 109 (B) HLA C*07 HCV E2 610-
618, Subject 109 (C) HLA A*02 HCV E2 614-622, Subject 18 (D) HLA A*11 HCV E2 621-628, 
Subject 109 (E) HLA A*29 HCV 97 790-799, Subject 109 (F) HLA A*02 HCV NS3 1073-1081, 
Subject 160 (G) HLA A*26 HCV NS3 1111-1120, Subject 109 (H) Sum of the magnitude of 
ELISpot response at peptide dilutions of 10, 1, and 0.1uM (y-axis) when peptides encoding 
bole1a or a naturally circulating variant was used to expand the T cells (x-axis). The lines connect 
the bole1a epitope to its corresponding variants. 
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Figure 5 Bole1a reliably expands T cells with diverse cross-reactivity 
PBMC were stimulated for twenty days with peptides bearing either the bole1a identified variant 
sequences. The resulting lines were tested against titrated concentrations of peptides encoding 
an HCV consensus sequence and identified variants in duplicate wells in an IFN-gamma ELISpot. 
(A) HLA A*01 HCV NS3 1436-1444, Subjects 113 and 65 (B) HLA A*11 HCV E2 621-628, 
Subjects 18 and 109 (C) HLA B*08 HCV NS3 1395-1403, Subjects 109 and 181 (D) HLA A*26 
HCV NS3 1111-1120, Subjects 109 and 18 (E) HLA C*07 HCV E2 610-618, Subjects 109 and 
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148 (F) HLA A*02 HCV NS3 1406-1415, Subjects 26 and 18 (G) HLA A*02 HCV NS3 1073-1081, 
Subjects 160 and 18. 
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Figure 6 Bole1a sequence contains the greatest number of optimal epitopes 
The optimal epitope sequence was defined as the sequence that induced the largest response or 
within 2-fold response of the largest response on IFN-gamma ELISpot at a peptide concentration 
of 1uM. Lines generated that produced only responses less than 100 SFC/1E6 cells were 
excluded from consideration. Full-length genotype 1a sequences culled from GenBank (n=390), 
cons1a, and bole1a sequences were then screened for the presence of the optimal epitopes and 





Approximately 170 million people worldwide are infected with hepatitis C virus (HCV) 
worldwide (1), including 2.7 million in the United States (3). Upon HCV infection, approximately 
2/3 of people will progress to chronic infection. Chronic HCV is the leading cause of 
hepatocellular carcinoma and liver transplantation (3,114) with acute infection often being 
asymptomatic. Direct-acting anti-viral medications not yet on the market promise sustained 
virological response rates of >90% without interferon use (73). However, such regimens are 
costly, and existing liver disease may continue to progress due to the existing severity of disease 
prior to therapy. As such, understanding the success and failure of the immune response may 
yield additional strategies to combat the virus in addition to enhancing vaccine responses. 
The high error-prone rate of the HCV polymerase coupled with its rapid replication rate 
quickly generates a diverse quasispecies of genetically related viruses (13) with 10
12
 virions 
produced each day(115). Thus, a durable immune response must respond to and control a 
genetically flexible virus. Studies in chimpanzees and humans have linked spontaneous 
clearance with favorable genetic SNPs (116), production of cytokines (117), development of CD4 
T cell responses (118), and a broad CD8+ T cell response (19,119). Conversely, failure of the 
CD8+ T cell response has been linked to a weak and narrowly focused response (37,72), 
mutations in viral sequence within known T cell epitopes (17,83), poor CD4 help (118,120), high 
numbers of Treg cells (121), and expression of co-inhibitory molecules including PD-1 (60,61,81), 
TIM-3 (122,123), LAG-3 (124), 2B4 (CD244) (124,125), KLRG1 (125,126), and CD160 (124,125). 
Studies in other chronic viral infections, including the lymphocytic choriomeningitis virus (LCMV) 
murine model (62,127) and HIV (82,128,129) have shown similar findings with an increasing 
number of inhibitory receptors correlating with diminished function (127). Whether additional 
inhibitory receptors function individually or synergistically to regulate adaptive immune cells 
during acute and chronic infection is not known, but blockade of one or more of the co-inhibitory 
molecules results in improved proliferation, expansion and cytokine function in some studies. 
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In general, it is thought that the severity of exhaustion correlates with the number of 
different receptors expressed, as well as the level of expression of each individual receptor (130). 
Functionally distinct subpopulations of exhausted CD8
+
 T cells express unique combinations of 
inhibitory receptors that respond differently to inhibitory receptor blockade. In the LCMV model, 
chronic viral infection is associated with higher levels of viremia and greater number of inhibitory 
receptors that are sustained over time (127,130). However, in infections with frequent mutation, 
the role of antigen persistence in their coexpression has not been defined. 
Inhibitory molecules such as PD-1 are up-regulated during acute HCV infection in 
individuals who clear as well as in those who progress to chronic infection (81). As such, it is 
possible that PD-1 is upregulated immediately following initial activation to ensure that the cell is 
refractory to further stimuli. Activation markers such as HLA-DR and CD38 have similarly been 
shown to be up-regulated in the setting of acute herpes virus infections, including human 
cytomegalovirus (CMV) and Epstein Barr Virus (EBV) (131,132). Similarly, CD38 expression 
increases during acute HCV infection with decreased expression over time (133). 
Previous studies have examined the relationship of T cell dysfunction and circulating 
sequence mutations by comparing the identified circulating sequence to a reference sequence, 
such as a consensus sequence or a phylogenetic approach (97,134). Because acute HCV 
infection is often asymptomatic, most studies are unable to discern the infecting sequence prior to 
the onset of the adaptive immune response. Longitudinally following an acutely infected cohort 
(70) provides the unique opportunity to examine the concerted dance of viral sequence 
substitutions within T cell epitopes and T cell responses over time. 
Given the role of inhibitory receptors in modulating T cell activation, it is also possible that 
inhibitory receptors shape the populations of effector and memory cells that develop during acute 
infections (135). Interleukin (IL)-7 signaling is essential to CD8 T-cell proliferation and function. 
The α chain of the IL-7 receptor (CD127) identifies effector CD8 T cells that will differentiate into 
memory cells with its selective expression identifying memory T cell precursors. During viral 
infection, CD127 expression on CD8 T cells occurs only when the pathogen is controlled so 
antigen is no longer present and sufficient CD4 T-cell help is available (136,137). Persistent viral 
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antigen is associated with low CD127 expression on primed T cells and correlates with 
exhaustion of a previously stable primed T-cell population (138). Therefore, we also assessed the 
relationship between CD127 expression and expression of inhibitory molecules. 
We hypothesized that T cell activation and upregulation of inhibitory molecules requires 
on ongoing recognition of the virus with engagement of the T cell receptor. We conducted 
longitudinal viral sequencing of ten subjects with T cells available for flow cytometry staining for 
activation, co-inhibitory, and memory markers. Here, we present longitudinal data on CD8+ T cell 






The Baltimore Before and After Acute Study
 
of Hepatitis (BBAASH) cohort of injection 
drug users (IDU) is a prospective study of injection drug users at risk for hepatitis C infection. 
Eligible participants have a history of or ongoing intravenous drug use and are seronegative for 
anti-HCV antibodies at enrollment. Written consent was obtained from each participant. Once 
enrolled, participants receive counseling to reduce intravenous drug use and its complications 
(70). Blood is drawn for isolation of serum, plasma, and peripheral blood mononuclear cells 
(PBMC) in a protocol designed for monthly follow-up. Participants with acute HCV infection were 
referred for evaluation of treatment. The study was approved by the Institutional Review Board at 
the Johns Hopkins School of Medicine. 
For infected subjects in the BBAASH cohort, the date of initial viremia is defined as either 
1) the first visit if HCV RNA is detectable in the absence of HCV Ab on enrollement or 2) the 
midpoint between the last RNA negative and first RNA positive date if initial viremia occurs on 
subsequent visits. For this study, we selected subjects from the BBAASH cohort who met the 
following criteria: 1) HCV Ab negative upon enrollment; 2) Initial viremia at the first visit (acutely 
infected on enrollment) or within 60 days of the last HCV RNA negative specimen in those with 
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viremia at later visits. ; 3) identified T cell responses by IFN-gamma ELISpot screen for which 
MHC multimers are available 4) T cells available for flow cytometry, 5) plasma available prior to 
the development of adaptive immune responses and 6) viremia at levels sufficient for HCV RNA 
sequencing at multiple time points. 
 
Flow cytometry 
PBMC were thawed in RPMI+50% FCS. Cells were stained for viability using the Cell 
Viability Dye (Invitrogen). Cells were stained for 20 min at room temperature with commercially 
available or custom-made APC-conjugated pentamers (ProImmune) with the exception of an 
APC-conjugated tetramer from the NIH Reagent Bank (HSKKKCDEL). Cells were additionally 
stained with the following antihuman fluorescent antibodies: anti-CD244 FITC, anti-TIM-3 PE 
(R&D), CD8 V450, PD-1 biotin (Mederex) and avidin-QDOT585 (Invitrogen), CD38 QDOT605 
(Invitrogen), CD3 QDOT655 (Invitrogen), HLA-DR APC-H7.  
Samples were run on a BD LSR-II instrument. Events for the entire content of the tube 
were collected with a minimum of 300,000 events per tube. Flow cytometry data was 
compensated in FACS Diva. Cells were gated on viable, CD3+ CD8+ cells in Flowjo. Gated data 
was exported to R where graphs and analysis was performed. 
 
Hemigenome sequencing: 
A 5.2 kb region spanning from Core through NS3 was amplified as described previously 
(98) with the exception that RT was performed using Superscript III (Invitrogen) and PCR was 
performed using Accuprime Pfx (Invitrogen). Amplicons were cloned into the pCR-XL TOPO 
vector using the TOPO-XL PCR cloning kit (Invitrogen). A 603 bp region from E1/E2 containing 
hypervariable region 1 was sequenced using the sequencing primer H77-1868a21 (5’-
GAAGCAATAYACYGGRCCACA-3’).  Sequence contigs were assembled in CodonCode Aligner 
(version 2.0.6, CodonCorp, Dedham, MA) and analyzed in BioEdit (version 7.0.9.0) with 
alignment using Clustal X. Phylogenetic trees were built based on these sequences, and a 
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representative clone nearest the center of the tree (139)was selected for further sequencing of 
the desired epitope. 
 
Interferon-gamma ELISpot Assay 
Ex vivo HCV CD8+ T cell responses were quantified by Human IFN gamma ELISPOT 
assays as previously described (37). Briefly, PBMC were screened for recognition of HCV-
specific antigens using pools of overlapping peptides covering the entire HCV polyprotein and 
previously defined optimal epitopes. PVDF plates were coated with 2.5ug/ml recombinant human 
anti-IFN-gamma antibody (Endogen M-700A) in 100ul PBS/well at 37ºC at 4ºC overnight. Plates 
were washed with sterile PBS eight times before blocking with RPMI +10% FCS for 30 minutes. 
Either 20,000 or 30,000 cells in R10 media were added to the well. PHA served as a positive 
control. Plates were incubated for 20 hours at 37ºC with 5%CO2. Following incubation, plates 
were washed with 200ul sterile PBS eight times and blotted dry. Biotin-labeled anti-IFN-gamma 
(Endogen, M-701B, 0.25ug/ml, 100ul) was added to each well and incubated for 90 min at room 
temperature. Plates were washed and incubated with streptavidin-alkaline phosphatase (Bio-Rad 
170-3554, 100ul) for 45 minutes at room temperature. Following additional washes, the plates 
were developed with BCIP/NBT Tris-buffer (pH 9.5) solution (Bio-Rad, 170-6532 and 170-6539) 




Identification of longitudinal changes in epitope sequence were performed in R v 2.13.2 
(140). Fasta files containing 5.2kb HCV sequences were aligned to the genotype 1a sequence, 
H77 in BioEdit and then converted to amino acid sequence. MHC Class I epitopes were identified 
based on their position in the H77 genotype 1a sequence. The sequence of these epitopes within 
the HCV sequences were extracted using the bio3d package (141) as well as unique code written 
in R. The initial infecting HCV sequence was defined as earliest representative sequence 
identified prior to 60 days of infection. This was chosen to select sequences that could be 
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identified prior to the onset of the adaptive immune response. Changes in sequence were 
identified as changes in amino acid sequence away from the initial infecting sequence. Where 
multiple clones were sequenced, both sequences were considered relative to the initial infecting 
sequence for potential mutations.  
Line graphs and correlations were generated using the R base package. Data were 
organized using the reshape package(142). Boxplots and pie graphs were generated using the 
ggplot2 package (143). 
 
Results 
We identified 10 acutely HCV infected subjects who met all criteria including plasma 
available prior to the development of adaptive (T cells and antibody) immune responses, viremia 
at sequenceable levels, and subsequent development of multimer-quantifiable T cell responses. 
Subject characteristics are delineated in Table 6. We sequenced circulating HCV using a clonal 
sequence method and compared clones from later time points to the earliest sequenced virus for 
that individual (Table 7). We isolated and sequenced virus within the first 60 days of infection for 
all 10 subjects. Via flow cytometry, we assessed levels of activation molecules (CD38 and HLA-
DR), a memory molecule (CD127), and inhibitory molecules (PD-1, TIM-3, and 2B4). These 
inhibitory molecules were selected based on their having detectable levels on peripheral T cells at 
some point in HCV infection. We then compared differences in surface expression of these 
molecules on HCV-specific T cells based on viral sequence variation and duration of infection. 
For seven subjects, we were able to isolate and stain T cells obtained during the acute phase of 
infection. However, for subjects 115 and 65, we were only able to isolate antigen-specific cells at 
38 weeks and 339 weeks after initial infection, respectively. 
When multiple clades of virus were found, as in chronic infection, multiple clones were 
sequenced. Given that any intact viral sequence could induce recognition and T cell receptor 
signaling, we considered sequence intact at any time points having any intact viral sequence 
even if that clone did not represent the majority of sequences. 
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Subjects in early acute infection show global activation of HLA-DR and CD38. 
The earliest phase of acute HCV infection is characterized by viremia without T cell 
responses, which are first detected 6-8 weeks into infection (144). The total CD3+CD8+ T cell 
population as well as T cells specific for HCV (once detectable), CMV, and EBV antigens 
(pentamer positive) were phenotyped throughout the course of HCV infection. The results were 
correlated with antigen status: 1) no detectable viremia (absent), 2) viremic and specific antigen 
intact (intact) or 3) viremia but specific antigen mutated to an unrecognized form (mutated).  
Further subsetting of mutated antigens was done so that mutations that impair T cell recognition 
in vitro were separated from those that don’t have effects on recognition that can be measured in 
an in vitro HLA binding affinity (145). Representative CD38 and HLA-DR staining is shown in 
Figure 7 for a robust T cell response to HCV. HCV specific T cell responses ranged in the first 
180 days of infection from 0.01- 2.58% of total CD8+ T cells. We identified two subjects from 
whom we could isolate and stain cells in the hyper acute phase of infection. Surprisingly, 27-30% 
of the global CD8+ population dually expressed HLA-DR and CD38 at 6 and 7 weeks of HCV 
infection (Figure 8A and B), suggestive of bystander activation. These levels then diminished to 
4-17% over time. This effect was true for antigen-specific cells specific for latent (EBV, CMV) or 
previously controlled (Influenza (Flu)) viruses as well. In these two subjects, 27-33% of EBV, 
CMV, and Flu-specific cells dually expressed HLA-DR and CD38 at weeks 6 and 7, percentages 
which declined to 0-15% at later time points. 
In contrast to the earliest time points, the global CD8+ T cell population and T cells 
specific for control viruses generally did not show marked dual expression of HLA-DR and CD38 
after the first 8 weeks of HCV infection (Figure 8C-J). There were some exceptions with dual 
expression seen on more than 25% of flu-specific cells from Subject 269 (weeks 11 and 49) and 
Subject 57 (weeks 13 and 33), CMV-specific cells from Subject 57 (week 47) and EBV-specific 
cells from Subject 18 (weeks 167, 244 and 314) and Subject 111 (week 12). In addition, Subject 
115 expressed HLA-DR and CD38 on more than 50% of T cell specific for two CMV epitopes 
(IPSI and TPRV) at multiple time points despite having little expression of HLA-DR and CD38 on 
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EBV, influenza, and global CD8+ T cells (Figure 8H). None of the subjects was febrile or 
otherwise obviously ill at the time that the samples were collected. 
Focusing on the HCV-specific response, HCV-specific CD8+ T cells showed high levels 
of activation and had higher level expression of activation markers than the global population with 
only a few exceptions. For Subject 175, 25% of T cells specific for the C63B HCV epitope had 
dual expression of HLA-DR and CD38 at week 6 with expression between that and 86% through 
week 99 (Figure 8A). CD8+ T cells from Subject 175 specific for the epitope E2 614-622 were not 
identified until week 29 but when identified, 84% dually expressed these activation markers, a 
number which declined steadily through week 99 of infection. HCV-specific cells identified also 
showed steady decline in dual expression of HLA-DR and CD38 from at week 6 in Subject 461 
dually expressed HLA-DR and CD38 to week 33 (Figure 8B). Declining dual expression of HLA-
DR and CD38 was observed on several other HCV-specific T cell populations identified outside 
the first 8 weeks of infection as well, although not uniformly (Figure 8C-J). We then asked if low 
levels of HLA-DR and CD38 on HCV-specific cells were due to mutations in the antigen that 
prevented T cell recognition. 
 
HCV-specific CD8+ T cells show greater HLA-DR and CD38 expression when the circulating viral 
sequence is intact relative to the initially identified circulating sequence. 
HLA-DR and CD38 have been identified as markers of activation. We hypothesized that 
coexpression of HLA-DR and CD38 would positively correlate with recognition of cognate antigen 
and would be negatively correlated with control of virus or substitutions within T cell epitopes that 
abrogate recognition. Although declining dual expression was observed on T cells specific for 
HCV in Subjects 175 and 461 despite persistent viremia with no mutations in targeted HCV 
antigens over time, the levels of activation remained high even in the late stages of infection 
(Table 7, Figure 8A, B). For Subject 26, 34% of cells expressed both HLA-DR and CD38 at week 
15, when cognate antigen was intact, with a decrease to 20% of antigen-specific cells activated 
following clearance of viremia (Figure 8C). Due to low viremia at week 49 for Subject 269, viral 
sequencing could only be performed at weeks 11 and 20, when 29 and 38% of the HCV-specific 
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cells dually expressed HLA-DR and CD38, respectively (Table 7, Figure 8D). The HLA B*08-
restricted epitope C171A mutation K1398R observed has been previously shown to permit 
ongoing T cell recognition, potentially permitting continued recognition and a high percent of 
C171A-specific T cells to be activated (107). 
Subject 57 cleared initial infection and had an identified reinfection at week 47. T cells 
obtained during his initial infection as well as prior to and after his reinfection were phenotyped 
(Figure 8E). Unfortunately, due to the low level of viremia during his second infection, we were 
unable to sequence that virus. Interestingly, we found that HCV-specific cells for this individual 
showed persistently high level activation of T cells specific for two epitopes and low levels of 
activation of T cells specific for two other epitopes. Throughout the initial infection and reinfection, 
HCV-specific cells recognizing the 140G and the C63B showed consistently low coexpression 
levels with 7-15% expressing HLA-DR and CD38. The exception occurred at week 58, when 
140G epitope-specific T cells had 29% dual expression. In contrast, T cells specific for the 4H 
and A2-61 epitopes showed higher levels of HLA-DR and CD38 dual expression, ranging from 
15-50% of cells. Thus, activation patterns are not constant on T cells specific for all epitopes 
following control of infection and the activated state may persist for variable lengths of time 
following successful control of an infection.  
High levels of activation, as evidenced by dual HLA-DR and CD38 expression, were not 
only seen following control of infection, but could also be seen late in chronic infection. In Subject 
30, we identified substitutions at the 9
th
 position within the epitope for both HLA A*02 epitopes 
A2-61 and C63B (Table 7). For the epitope A2-61, a valine or isoleucine at amino acid position 
622 binds the major histocompatibility complex with similar affinity. T cells lines generated against 
the E2 614-22 peptide RLWHYPCTI as well as the NS3 1073-1081 peptide CINGVCWTV retain 
the capacity to recognize the V622 and I1081 variant, respectively (146). Perhaps not surprisingly, 
50 and 63% of T cells specific for these epitopes, respectively, maintained dual expression of 
HLA-DR and CD38 (Figure 8F). This suggests that ongoing recognition is possible, despite 
substitution within the HLA- binding region. 
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Retention of cognate antigen or reversion to the cognate sequence over time was not 
associated with a consistent pattern of activation. Subject 18 cleared an initial infection but 
became persistently infected following re-infection at week 24. T cells specific for three of four 
HCV epitopes showed increased dual expression of HLA-DR and CD38 at the time of reinfection, 
and two of these epitope retained high levels of activation through week 45 (Figure 8G). Notably, 
the sequenced virus in reinfection showed no changes in viral sequence from the initial viral 
sequence for the C63B or 140G epitopes (Table 7). However, the effects of ongoing stimulation 
differed in that T cells specific for C63B maintained high level activation, but T cells specific for 
140G did not. In Subject 115, who became chronically infected with the first HCV infection, 80% 
of CD8+ T cells specific for the 140G epitope showed high levels of HLA-DR and CD38 
expression at week 38, which declined to 19% by week 57 and 0% by week 93 (Figure 8H). A 
circulating substitution within the 140G epitope was identified at the K1406N position at week 64 
with reversion to the initial infecting sequence at week 93, suggesting that other factors in 
addition to viral sequence variation may play a role. 
Both Subjects 115 and 65 were found to carry the Y1444F mutation relative to the initial 
infecting sequence in the 143D epitope (Table 7). The predominant Y1444F substitution impairs 
binding to the HLA-A*01 molecule, but carries a fitness cost so reversion to Y is common is the 
absence of T cell pressure (95). In both cases, HLA-DR and CD38 expression on CD8+ T cells 
specific for the 143D epitope ranged from 5-21% (Figures 8 H and I), which suggests that the F 
substitution is maintained by ongoing activated CD8 T cell pressure. While Subject 111 also 
targets the 143D epitope, there is no significant dual expression on T cells specific for that 
epitope despite the presence of F in the last position. However, that subject was infected with 
143D bearing F in the last position and may not ever have activated T cells specific for the better 
recognized Y variant. 
Figure 9 shows HLA-DR and CD38 dual expression frequency for all subjects combined 
according to the virus targeted versus the general CD8+ T cell population. Collectively, the global  
CD8+ T cell population and T cells specific for EBV and resolved influenza viral infection showed 
low levels of HLA-DR and CD38 (Figure 9A). CMV-specific CD8+ T cells showed a greater range 
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of HLA-DR and CD38 dual expression. (Figure 9A) The percent of HLA-DR and CD38 
coexpression was more variable on HCV specific T cells. Overall, we detected higher levels of 
HLA-DR and CD38 coexpression when the viral sequence was intact than when the viral 
sequence contained substitutions or when the virus was controlled (undetectable HCV RNA). 
Mutations known to impair T cell recognition in vitro were associated with less dual expression. 
Interestingly, differences in HLA-DR and CD38 coexpression were even greater when stratified 
by prior to or after 180 days of infection (Figure 9B), suggestive of an initial activation in the 
setting of acute infection that decreases over time. Given that increased duration of infection has 
been hypothesized to result in upregulation of progressively more inhibitory receptors that 
decrease T cell proliferation and cytokine production, we assessed expression of such inhibitors.  
 
Subjects in early acute infection showed elevated global levels of co-inhibitory markers. 
Co-inhibitory markers such as PD-1, TIM-3, and 2B4 have been shown to be expressed 
at high levels on T cells in subjects who progress to chronic infection. We hypothesized that 
inhibitory receptor expression is coordinately upregulated and maintained over time and 
correlates inversely with high levels of activation. We examined PD-1, TIM-3, and CD244 (2B4) 
expression on the global CD8+ population, CD8+ cells specific for the latent viruses CMV and 
EBV, CD8+ cells specific for prior influenza infection, and HCV-specific cells. Representative flow 
cytometry is shown in Figure 10A with T cells from subjects stained longitudinally in Figures 11A-
J. 
The earliest phase of the adaptive immune response demonstrated minimal increase in 
the number of co-inhibitory receptors expressed on the global CD8+ T cell population versus later 
time points in HCV infection. In the two subjects with cells isolated before 8 weeks of infection, 
approximately 11% of the global CD8+ T cell population expressed two or three co-inhibitory 
receptors at this time point, a number which declined to less than 5% expressing two receptors 
and no expression of three inhibitory receptors in the subsequent weeks (Figure 11A and B). 
Interestingly, T cells specific for EBV, CMV, and influenza also had maximal co-inhibitory receptor 
expression during this earliest acute phase of HCV infection. At less than 8 weeks of infection, 
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24% of EBV-specific cells, 26% of CMV-specific cells, and 50% of influenza-specific cells 
expressed either two or three co-inhibitory molecules. By 29-33 weeks of infection, the percent of 
control-virus specific T cells with at least two co-inhibitory receptors declined to 14% for flu 
(Figure 11A) and 10% or 4% for EBV and CMV, respectively (Figure 11B). 
Notably, in Subject 175, 75% of cells specific for the HCV epitope C63B had no 
expression of any inhibitory receptors at 6 weeks of infection compared to 37% of cells specific 
for that same epitope at week 7 for subject 461. Subject 175 demonstrated an increase in the 
number of co-inhibitory receptors between weeks 6 and 53, before declining by week 99 (Figure 
11A). For Subject 461, however, the percentage of HCV-specific cells that expressed either two 
or three co-inhibitory receptors peaked at week 7 with 35 and 61% for the epitopes 4H and C63B 
before declining to 5 and 22%, respectively, by week 33 (Figure 11B). Both subjects became 
persistently infected so the difference in coinhibitory receptor expression was not associated with 
a different infection outcome. 
 
Expression patterns of inhibitory T cell receptors change variably over time, are not progressively 
(or sequentially) upregulated and may correlate with antigen-status 
We found that the patterns of co-inhibitory molecules on HCV-specific cells varied by 
subject as well as by epitope but generally declined over time, regardless of outcome. Such 
patterns did not clearly correlate with the presence or absence of viremia in those who cleared 
infection. Subjects 18, 26, and 57 cleared their initial viremia (Table 6). In the case of Subject 18, 
the number of co-inhibitory receptors remained constant on T cells specific for the 127D, 140G, 
and A2-61 epitopes (Figure 11H). In contrast, the percentage of T cells specific for C63B with at 
least two co-inhibitory receptors declined from 27% in week 14 to 8% in week 111, an aviremic 
time point between his first and second infection. However, this percentage increased by weeks 
244 and 314, over 60 and 110 weeks into his second infection. The sequence of virus in epitope 
C63B remained intact at all points tested, so loss of antigen neither explained the difference 
between T cell inhibitory receptor expression levels over time nor between epitopes in the same 
subject. Subject 26 had 19% of HCV-specific T cells with two or three co-inhibitory receptors 
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during infection with a decline  to 11% following clearance of infection, but that decline was driven 
by loss of cells with two receptors since the percent of cells with three receptors increased slightly 
(Figure 11C). For Subject 57, T cells specific for epitopes 4H and A2-61 showed greater 
expression of two or more inhibitory receptors at 33 and 47 weeks than during initial infection, but 
that was not true of T cells directed against two other HCV epitopes recognized by the same 
subject. The dual expression of two or three inhibitors declined through week 68 but increased 
again at week 166, despite the absence of detectable viremia after week 47 (Figure 11E). 
Not only did patterns of inhibitory receptor expression not differ between those who 
controlled infection and those who did not, there was neither a consistent increase in the number 
of inhibitory receptors expressed over time with chronic HCV infection nor a correlation with 
maintenance of intact antigen and higher numbers of coinhibitory receptors being expressed 
throughout infection. Subject 30 had identified substitutions at the 9
th
 position within the two HLA 
A*02 epitopes studied. For the A2-61 epitope, at weeks 95 and 192, only 3-7% of HCV-specific T 
cells had more than one inhibitory receptors present. However, at weeks 261 and 425, these 
numbers increased to a range of 10-13%. In comparison, T cells recognizing the C63B epitope 
had 36% of cells with at least two co-inhibitory receptors, a number which declined to 6% by 
week 425 (Figure 11F). It is possible that the in vivo effects of these mutations differed between 
the two epitopes, explaining their different pattern over time. However, the effect of mutation on 
coinhibitory molecule expression does not appear to be consistent across epitopes, even in the 
same subject. 
This point is further illustrated by Subject 115, where the 140G epitope undergoes 
mutation between week 38 and 64 with reversion to the initial infecting sequence by week 93. In 
the same subject, the 143D mutates from Y to F in the last position between weeks 3 and 38 of 
infection and remains stable throughout the infection (Table 7). T cells specific against the 140G 
showed declining levels of double and triple expression ( around 48% initially) while  T cells 
specific for the 143D epitope, initially expressed at least two co-inhibitory molecules on only 14% 
of cells which declined to 4% by week 93 (Figure 11H). Similarly, only 5% of T cells specific for 
the 143D epitope from Subject 65, who also maintains the Y1444F mutation (Table 7) have two 
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or more co-inhibitory receptors (Figure 11 I). Although the circulating virus has phenylalanine in 
the 1444 position for Subject 111 (Table 7), this was the sequence initially isolated at week 
6.Only 1-3% of T cells express more than one co-inhibitory receptor. In comparison, 40% T cells 
specific for the C171A epitope express more than one co-inhibitory receptor at 12 weeks, a 
percentage that decreased to 0% at 29 weeks (Figure 11J). For subject 269, 20% of HCV cells 
specific for the C171A epitope expressed two inhibitory receptors at 11 weeks, a number which 
declined to 15% at week 49, but increasing the number of cells expressing three co-inhibitory 
receptors from 0 to 5% (Figure 11D). Altogether, these snapshots suggest a far more complex 
picture with some decline over time of inhibitory molecule expression rather than progressive 
increases in the number of coinhibitory receptors as has been shown in murine LCMV (130).  
 
Analysis of inhibitory receptor expression by antigen status reveals more complex regulation.  
We then grouped the circulating viral sequence by epitopes status: intact, mutated, low 
HCV RNA (detectable but not sequenceable), or absent (undetectable HCV RNA) relative to the 
initially identified circulating virus and CD8+ T cells based on expression of inhibitory receptors. 
Antigen status is shown with the percent single expression of PD-1, TIM-3, or 2B4 in Figure 12A, 
expression of two of the three—either PD-1/TIM-3, PD-1/2B4, or TIM-3/2B4 in Figure 12B, or 
triple expression of all three markers in Figure 12C. Overall, antigen-specific and global CD8+ T 
cells had low single expression of PD-1 with the most single-expression being found on HCV-
specific cells where the circulating viral sequence was absent relative to the initially identified 
infecting sequence (Figure 12A). Interestingly, influenza-specific cells stained highly for TIM-3 
single expression whereas CMV- and EBV-specific cells expressed higher levels of 2B4. In HCV 
infection, high frequency coexpression of PD-1 and TIM-3 (>12% of antigen specific T cells) 
occurred exclusively when the virus was intact (Figure 12B, first panel) One flu exposed subject, 
also had more than 12% of T cells coexpressing PD-1 and TIM-3, but high frequency PD-1/TIM-3 
coexpression was not observed on EBV-specific, CMV-specific, or the general CD8 T cell 
populations of the same subject.  PD-1/2B4 coexpression was detected at higher levels on EBV-
specific, CMV-specific, and HCV specific T cells than on the general CD8 T cell population with 
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lower percent coexpression on HCV-specific T cells when the antigen was intact.(Figure 12B, 
middle panel) This suggests that continued antigenic stimulation is not associated with 
upregulation of both inhibitory molecules. Coexpression of TIM-3 and 2B4 was infrequent, with 
only five T cell populations, three of which were CMV-specific T cells, having >15% of cells with 
dual TIM-3 and 2B4 expression (Figure 12B, last panel). No subject had HCV-specific T cells with 
more than 15% TIM-3 and 2B4 coexpression. 
Across all subjects and time points, less than 7% of the global CD8+ population 
expressed two or all three co-inhibitory receptors outside of the initial 6-7 weeks of infection 
(Figures 12B and 12C). Some subjects with intact antigen have a small percent of antigen 
specific T cells with triple expression of PD-1/TIM3/2B4 (Figure 12C). Thus, cognate antigen may 
be associated with the highest levels of expression, but is not sufficient to induce expression of all 
three inhibitory receptors. 
 
Expression patterns of inhibitory T cell receptors correlate with dual expression of HLA-DR and 
CD38. 
No definitive pattern clearly emerged as a signature of CD8+ HCV-specific T cells after 
dividing based on the absence of viremia, low VL, or intact antigen, or presence of substitutions. 
Given the increasing complexity of the quasispecies in chronic infection, we hypothesized that the 
dual combination of HLA-DR and CD38 may better illuminate the role of the co-inhibitory 
receptors and CD127. Preliminary analysis of HLA-DR and CD38 separately showed weaker 
trends (data not shown). Representative T cell staining for CD127 is shown in Figure 13. We 
compared the percentage of cells dually expressing HLA-DR and CD38+ and the expression of 
2B4, PD-1, TIM-3, and CD127 and combinations of PD-1, TIM-3, and 2B4 (Figure 14). Due to the 
generally low expression of CD127 on HCV-specific cells, we did not examine the relationship 
between CD127 and co-inhibitory receptor expression. HLA-DR/CD38+ dual expression weakly 
correlated with PD-1 expression (Figure 14A, r
2
=0.145, p=8.01e-5), TIM-3 expression (Figure 
14B, r
2
=0.229, p=3.54e-7), and 2B4 expression (Figure 14C, r
2
=0.169, p=1.81e-5). HLA-DR and 




p=9.88e-8). Interestingly, a strong correlation was seen between HLA-DR/CD38 dual expression 
and dual PD-1/TIM-3 expression (Figure 14E, r
2
=0.367, p=1.5e-11), with weak or no correlation 
seen between HLA-DR/CD38 dual expression and dual PD-1/2B4 (Figure 14F, r
2
=0.0974, 
p=0.0014), or dual TIM-3/2B4 (Figure 14G, r
2
=0.0206, p=0.15) expression. However, the 
strongest positive correlation was seen between HLA-DR/CD38 and triple expression of PD-1, 
TIM-3, and 2B4 (Figure 14H, r
2
=0.367, p=1.5e-11). This suggests a relationship between 
activation and expression of co-inhibitory receptors, a surprising finding suggestive of activation 
not exhaustion when all three are expressed. We then looked at activation state (as measured by 
IFN-γ production) in association with recognition over time. 
 
Functional responses do no track along CD8+ T cell responses. 
In the setting of HCV infection, the breadth and frequency of the CD8+ T cell response 
has been shown to decline over time (37,147). HCV-specific T cell responses are generally of 
lower magnitude than are T cell responses to HIV (148). T cell responses to HCV are particularly 
infrequent and of low magnitude in the setting of chronic infection. The low precursor frequency of 
these antigen-specific cells precluded us from performing intracellular cytokine staining. At each 
visit where pentamer staining was performed, we screened our subjects for functional responses 
by IFN-gamma ELISpot. Despite maintaining clearly identifiable populations of antigen-specific T 
cells by pentamer staining, most subjects lost their functional responses in chronic infection 
(Figure 15). Thus, irrespective of expression of the three molecules associated with exhaustion 
that we assessed, there is loss of gamma interferon production after 100 weeks of infection of 
most HCV-specific CD8 T cell responses. The exception after 100 weeks of infection included the 
response to the C171A epitope in Subject 269. T cells specific for that epitope did express all 
three inhibitory co-receptors at time points where IFN-γ was produced in response to antigen so 
the maintenance of gamma interferon expression was not related to failure to upregulate these 
molecules. T cell gamma interferon production was more durable in subjects who controlled 




We hypothesized that T cell dysfunction requires ongoing recognition of the virus to 
maintain an activated state and up regulation of co-inhibitory receptor expression. We performed 
longitudinal sequencing and flow cytometry on subjects to profile the relationship between viral 
sequence and cell surface phenotype. Much of our work hinges upon careful dating of the initial 
infection. Therefore, we selected subjects with frequent follow up to determine an estimated date 
of infection. 
We had two subjects with available samples at 6-7 weeks. Surprisingly, a large 
percentage of the global CD8+ population as well as T cells specific for controlled latent viruses, 
and cleared influenza virus showed high levels of co-expression of HLA-DR and CD38, 
suggestive of bystander activation that diminished over time. Notably, this was not present after 
week 11 of infection. In humans, bystander activation and attrition have been suggested in the 
context of acute primary EBV infection in the first 30 days of infection with elevated HLA-DR, 
CD38, and granzyme B expression on CMV and influenza-specific cells (132). Similarly, 
bystander activation with elevated CD38 expression has been proposed in the context of primary 
HIV infection in the setting of detectable RNA but prior to seroconversion (149). CMV-specific 
cells have further been characterized to have elevated PD-1 and low production of IFN-γ in the 
setting of acute HBV infection (150). This may be attributable to the fact that T cells specific for 
those infections are frequent. However, HCV-specific T cells are of low frequency in virtually all 
individuals and account for less than 5% of the total CD8 T cell population in virtually all cases. 
Although high CD38 expression has been previously described during the acute phase of 
HCV infection(133), we identified 5 out of 7 subjects with samples obtained after more a year of 
infection that still expressed HLA-DR and CD38 on HCV-specific T cells (Figure 10 A, E, F, G, 
and H). This suggests that ongoing activation of HCV-specific T cells is possible late in infection 
despite failure to produce IFN-γ in vitro upon stimulation. We had hypothesized that viral 
sequence and ongoing recognition may be the driving force. Consistent with that hypothesis, we 
saw higher co-expression of HLA-DR and CD38 on HCV-specific T cells where the cognate 
antigen was intact. We observed higher levels in the first 180 days of infection, but these high 
 63 
levels were maintained relative to the global CD8+ population after 180 days of infection. In a 
prior study examining CD38 on HCV-specific cells, CD38 was present on HCV specific T cells in 
acute infection but was not present in different subjects analyzed during chronic infection. (151). 
However, HCV sequence was not determined for these subjects. Given our data that CD38 and 
HLA-DR are not maintained on T cells specific for mutated antigen, it is probable that these 
subjects developed substitutions within the T cell epitope that precluded recognition. Mutations 
that don’t impair recognition by T cells in vitro were associated with T cell activation. What drives 
maintenance of these mutations in vivo is unclear since T cells seem to continue to recognize 
them and these viral variants persist in infected hosts. Intriguingly, recent vaccination studies in 
chimpanzees demonstrated that expression of HLA-DR with or without CD38 was correlated with 
improved proliferation and likelihood of clearance of HCV following vaccination (152). Whether 
this is just a marker of activation or of improved immune response remains to be seen. 
Our data showed an inverse relationship between HLA-DR and CD38 co-expression and 
CD127 expression (Figure 14D). This is consistent with previous work in HCV in which CD127 
(IL-7Ralpha) are also down-regulated in chronically infected individuals and particularly on T cells 
whose cognate antigen has not undergone substitutions (153). The presence of HCV-specific 
CD127+ cells predicted clearance in chimpanzees (154) and humans (155). However, because 
IL-7 is critical for the maintenance of memory T cell populations, it is unclear whether the 
presence of CD127 is causative or reflective of an already durable immune response. 
We did not see a clear signature of co-inhibitory molecule expression on the cell surface 
of antigen-specific T cells. There is a substantial body of literature on cross sectional analysis of 
individually inhibitory molecule expression in HCV infection with less on coexpression of multiple 
co-inhibitory molecules or longitudinal analysis. Our studies are the first to take into consideration 
the sequence of the virus to determine if there is continued production of cognate antigen. PD-1 
has been shown to be more likely to be expressed on HCV-specific T cells in the setting of acute 
infection (61,81), and up regulation of multiple inhibitory molecules has been associated with 
progression to chronic infection(122). Chronically infected patients have been shown to up 
regulate PD-1, 2B4, KLRG1, and CD160 (125) on HCV-specific CD8+ cells in the periphery. 
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Moreover, the patterns of co-inhibitory molecules differs based on organ site with higher levels of 
PD-1 and 2B4 found in the liver compared to the peripheral blood in chronically infected livers 
(124). 
The initial sequence identified in circulation among our subjects largely corresponded 
with the previously established bole1a sequence. The bole 1a sequence is a synthetic, 
representative clone that is phylogenetically derived using a primarily Bayesian approach (97). 
Such a sequence has been thought to minimize the degree of genetic dissimilarity between 
subjects. Differences from the bole1a sequence seen at initial infection arose primarily within the 
E2 614-622 (A2-61) epitope at the 9
th
 position within the epitope (I622A/V), the 143D epitope 
(Y1444F) and in the C171A epitope (K1398R, Table 7). The high level of activation of T cells 
primed with sequence that matches bole1a is consistent with it being a potent antigen (146) 
We demonstrate that HLA-DR and CD38 expression is associated with PD-1, TIM-3, dual 
expression, as well as triple expression in conjunction with 2B4. This suggests that ongoing 
activation is maintained despite the expression of the co-inhibitory receptors. Given that the 
inhibitory receptors are supposed to decrease activation of T cells, this is a surprising finding. Our 
data also demonstrate ongoing expression of CD38 and HLA-DR on HCV-specific T cells, 
suggesting that even late into chronic infection, populations of HCV-specific T cells continue to be 
activated in response to antigen despite the lack of detectable gamma-interferon production in 
late phases of infection. In total, this may suggest that expression of CD38 and HLA-DR may 
indicate recent activation but not the capacity of the T cell to produce cytokines.  
T cell breadth and frequency are known to decline following the acute phase of infection 
(156,157) and one hypothesis offered has been the progressive upregulation of inhibitory 
molecules. In the LCMV murine model, it has been postulated that there is a temporal relationship 
between time of infection and expression of co-inhibitory receptors. In an elegant comparison of 
three strains of LCMV infection, infection with Clone 13 resulted in the greatest number of co-
inhibitory receptors, compared with the acute infectious Armstrong strain or the intermediate T 
strain (127). Arguing against this hypothesis, we were able to identify T cells in acute infection 
with up regulation of multiple co-inhibitory molecules and T cells in late infection without high 
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percents of expression of two or more inhibitory molecules. In fact, many subjects had a gradual 
decline in the number of co-inhibitory receptors expressed. Perhaps not surprisingly given the 
complexity of the HCV quasispecies, we did not find a clear pattern of either up regulation or 
down regulation of co-inhibitory receptors on our subjects. Because we did not stain for classic 
memory markers, we don’t know if the cells being analyzed are memory or effector cells. In 
addition, it is unclear whether these cells late into chronic infection represent the same population 
of T cells initially activated and expressing co-inhibitory receptors or whether this population 
reflects priming of a different T cell population later in infection. 
Limitations of our study include that we were only able to profile ten subjects for 
longitudinal sequencing and comprehensive flow cytometry, of which only seven had available 
samples in the early acute (less than 8 weeks) phase of infection. Given that small sample size 
and multiple time points for each subject with multiple molecules assessed, statistics were 
complicated by the number of variables versus compared to the number of subjects. Furthermore, 
while we had clearly detectable antigen-specific T cells by pentamer staining, we were unable to 
perform intracellular cytokine staining to directly assess function along with cell surface 
phenotype and had to use ELISpot detection of IFN-γ as a surrogate. 
We categorized subjects based on whether there was circulating antigen and whether 
this antigen sequence was intact. If any intact antigen were present in any number of clones, we 
labeled that visit as having intact antigen. We reasoned that any T cells exposed to circulating 
virus could have the potential to be activated if a small fraction of the circulating sequence 
maintained intact cognate antigen. However, it is unclear whether a certain threshold of a 
quasispecies must have the same viral sequence to impact T cell function so this may not have 
been the correct way to code a specimen. Further complicating the analysis, although mutation 
more commonly arise in the setting of T cell pressure (17,107,158), their impact on T cell 
recognition is variable. The 143D epitope (HLA A*01 NS3 1436-1444) reduces viral fitness by 
reducing helicase function 10-fold (95). However, this substitution is extremely common in the 
HLA A*01 population, as the mutant Y1444F sequence reduces binding to the HLA by an 
estimated 1000-fold (146). In contrast, substitutions in A2-61 epitope (HLA A*02 E2 614-622) at 
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I622V occur in a known HLA binding motif but does not impair expansion or recognition in ex 
vivo-expanded T cell lines (146). Thus, the effect of substitutions on T cells is highly variable and 
likely relates balancing constraints on viral fitness. Therefore, categorizing circulating sequences 
as containing substitutions or intact antigen underestimates the complexity of the impact of the 
substitutions. We did analyze effects of inhibitory molecules in the presence of mutations taking 
into account known mutations where possible.  An additional complication is the variable data on 
2B4 as a costimulatory molecule rather than a coinhibitory molecule on effector T cells (135,159). 
Thus, the effects of expression of 2B4 may be context dependant, further complicating analysis of 
the effects of its expression. 
Overall, we determined that dual expression of HLA-DR and CD38 occurs in the setting 
of ongoing T cell recognition. Expression of both of these markers is associated with expression 
of greater expression of co-inhibitory receptors singly or in combination. Our work suggests that 
the role of the co-inhibitory receptors in making T cells less able to release the antiviral cytokine 
gamma interferon release is a complex process in which ongoing T cell recognition and activation 
is required, but not sufficient. 
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Table 6 Characteristics of subjects selected for longitudinal sequence analysis and flow 
cytometry 




Race Gender Outcome 
18 1a W M Clearance - reinfected 
26 1a W M Clearance 
30 1a W F Chronic 
57 1a W M Clearance - reinfected 
65 1a W M Chronic 
111 1a W F Chronic 
115 1a W M Chronic 
175 1a W M Chronic 
269 1a W F Chronic 




Table 7 Sequence data for subjects 
A 5.2kb region was amplified using a nested PCR technique and cloned into pCR-XL TOPO 
vector. A region of Core through E1 was sequenced to select a phylogenetically representative 
clone prior to sequencing of the region containing the epitope of interest. Where multiple clades 
were present, multiple clones were sequenced. 




18 A2-61 A02 E2 614-22 RLWHYPCTI 2 
  
    
--------V 214 
  
    
--------- 244 
  
    
--------- 314 
  C63B A02 NS3 1073-81 CINGVCWTV 2 
  
    
--------- 214 
  
    
--------- 244 
  127D A02 NS3 1273-82 GIDPNIRTGV 2 
  
    
-A-------- 214 
  
    
-A-------- 244 
  
    
-A-------- 314 
  140G A02 NS3 1406-15 KLVALGINAV 2 
  
    
---------- 214 
  
    
---------- 244 
          ---------- 314 
26 140G A02 NS3 1406-15 KLVALGINAV 2 
          ---------- 15 
30 A2-61 A02 E2 614-22 RLWHYPCTV 2 
  
    
--------I 95 
  
    
--------I 192 
  
    
--------I 261 
  
    
--------I 425 
  C63B A02 NS3 1073-81 CINGVCWTV 2 
  
    
--------I 95 
  
    
--------I 192 
  
    
--------I 261 
          --------- 425 
57 4H B07 Core 41-49 GPRLGVRAT 6 
  A2-61 A02 E2 614-22 RLWHYPCTA 6 
  C63B A02 NS3 1073-81 CINGVCWTV 6 
  140G A02 NS3 1406-15 KLVALGINAV 6 
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65 143D A01 NS3 1436-44 ATDTLMTGY 2 
  
    
--------F 339 
  
    
--------F 375 
          --------F 418 
111 C171A B08 NS3 1395-1403 HSKRKCDEL 6 
  
    
---K----F 12 
  
    
--------V 29 
  143D A01 NS3 1436-44 ATDALMTGF 6 
  
    
V-------- 12 
  
    
--------- 12 
  
    
--------- 21 
  
    
--------- 29 
          --------- 58 
115 140G A02 NS3 1406-15 KLVALGINAV 3 
  
    
---------- 38 
  
    
N--------- 64 
  
    
---------- 93 
  143D A01 NS3 1436-44 ATDALMTGY 3 
  
    
--------F 38 
  
    
--------F 64 
          --------F 93 
175 A2-61 A02 E2 614-22 RLWHYPCTA 0 
  
    
--------- 53 
  
    
--------- 69 
  
    
--------- 99 
  C63B A02 NS3 1073-81 CINGVCWTV 0 
  
    
--------- 6 
  
    
--------- 53 
  
    
--------- 69 
          --------- 99 
269 C171A B08 NS3 1395-1403 HSKKKCDEL 3 
          ---R----- 49 
461 4H B07 Core 41-49 GPRLGVRAT 0 
  
    
--------- 7 
  
    
--------- 17 
 C63B A02 NS3 1073-81 CINGVCWTV 0 
     --------- 7 
     --------- 17 
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Figure 7 Representative flow cytometry staining of HLA-DR and CD38 expression 
PBMCs from 10 HCV-infected subjects at multiple time points were stained and analyzed for 
CD3+CD8+ and antigen-specificity using pentamer technology. Cells were then analyzed for their 
expression of HLA-DR and CD38. Representative staining is shown for Subject 461. (A) 
Pentamer staining over 7, 17, and 33 weeks post infection. (B) CD38 and HLA-DR expression on 
the global CD8+ T cell population. (C) CD38 and HLA-DR expression on CD8+ T cells specific for 

















Figure 8 HLADR and CD38 are dually expressed throughout HCV infection 
PBMCs from 10 HCV-infected subjects at multiple time points were stained and analyzed for 
CD3+CD8+ and antigen-specificity using pentamer technology. HCV, CMV, EBV, Flu-specific, 
and global CD8 T cells were then analyzed for expression of HLA-DR and CD38.(A-J) with the 
percent of  single or double HLA-DR and CD38 expression shown and red shading indicating 
double expression. The horizontal axis indicates weeks post initial infection, and the vertical 





Figure 9 HLA-DR and CD38 are expressed on cells with intact circulating antigen. 
PBMCs from 10 HCV-infected subjects at multiple time points were stained and analyzed for 
CD3+CD8+ and antigen-specificity using pentamer technology. Cells were then analyzed for their 
expression of HLA-DR and CD38. Samples were grouped in the following categories: global 
CD8+ population, the control viruses CMV, EBV, and influenza, and HCV. HCV-specific cells 
were further stratified based on whether the identified circulating virus was intact, absent, or 
contained mutations known to impair binding to the HLA (mut imp) or did not impair binding to the 
HLA (mut non-imp). (A) All samples irrespective of time of infection (B) Samples stratified prior to 
and after 180 days of infection.  
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Figure 10 Representative FACS staining of PD-1, TIM-3, and 2B4 
For Subject 461, PBMCs were stained and gated on CD3+CD8+ and antigen-specificity using 



















Figure 11 Expression of co-inhibitory molecules diminishes over time. 
PBMCs from 10 HCV-infected subjects at multiple time points were stained and analyzed for 
CD3+CD8+ and antigen-specificity using pentamers. Cells were then analyzed for their 
expression of PD-1, TIM-3, and 2B4. The percentage of cells expressing zero, one, two ,or three 
inhibitory receptors (PD-1, TIM-3, 2B4) on HCV, CMV, EBV, Flu-specific, and global CD8 T cell 
population was calculated and expressed in a pie graph (A-J). The horizontal axis indicates 








Figure 12 Expression of co-inhibitory molecules differ based on circulating virus 
sequence. 
PBMCs from 10 HCV-infected subjects at multiple time points were stained and analyzed for 
CD3+CD8+ and antigen-specificity using pentamers. Cells were then analyzed for their 
expression of PD-1, TIM-3, and 2B4.. Samples were grouped in the following categories: global 
CD8+ population, the control viruses CMV, EBV, and influenza, and HCV. HCV-specific cells 
were further stratified based on whether the identified circulating virus was intact, absent, or 
contained mutations known to impair binding to the HLA (mut imp) or did not impair binding to the 
HLA (mut non-imp). (A) Percentage of cells with single expression of only PD-1, TIM-3, or 2B4. 
(B). Percentage of cells with dual expression patterns of PD-1/TIM-3, PD-1/2B4, and TIM-3/2B4. 
(C) Percentage of cells with triple expression of PD-1, TIM-3, and 2B4. 
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Figure 13 Representative FACS staining of CD127 
Representative FACS staining of CD127 on Subject 461 for weeks 7, 17, and 33. PBMCs were 
stained and gated on CD3+CD8+ and antigen-specificity using pentamer technology. Cells were 





Figure 14 Triple expression of co-inhibitory molecules is strong positively correlated with 
HLA-DRA and CD38 dual expression on HCV-specific CD8+ T cells 
Cells were analyzed by flow cytometry for expression of co-inhibitory molecules PD-1, TIM-3, and 
2B4, the differentiation molecule CD127, and the activation markers HLA-DR and CD38. Patterns 
of inhibitory receptor and CD127 expression HLA-DR+ CD38+dual expression (x-axis) versus 
CD127 or co-inhibitory receptor (y-axis). (A) PD-1 (B) TIM-3 (C) 2B4 (D) CD127 (E) PD-1 and 





Figure 15 Antigen-specific cells are detectable after functional response is not detectable. 
Shaded region indicates RNA viremia (IU/ml, right y-axis). Line graphs indicate percent 
of pentamer-specific events per CD8+ population (left y-axis) versus weeks post initial 
viremia. Symbols indicate viral sequence intact (-●-), viral sequence with substitutions 
relative to initial viremia (-○-), viral sequence absent (-◊-), or unable to be sequenced (-
‎∆-). At these time points, sequences were also tested for IFN-γ response by ELISpot 
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with positive ( + ) or negative ( - ) responses indicated at the given time point. Colors 
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